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Altered ovarian cancer metabolism increases the neuronal n-acetylaspartate to 
promote tumor growth 
Publication No._____ 
Behrouz Zand, M.D. 
Supervisory Professor:  Anil K. Sood, M.D. 
Background:  Altered metabolism is a well-established trait in many cancers, and is 
an emerging hallmark of cancer.  Recent resurgence of cancer metabolism studies 
has identified dysregulated metabolic pathways that produce novel oncometabolites 
in various cancers.  However, large scale studies of dysregualted high grade serous 
epithelial ovarian cancers (HGSOC) are unknown.       
Materials and Methods:  Following IRB approval, metabolic profiling of 101 
HGSOC patients and 15 normal ovaries were obtained using GC/LC mass 
spectrometry from 2 U.S. academic centers to identify highly up-regulated 
metabolites.  Samples from a cohort of 135 and 208 patients from a single 
institution were evaluated for gene expression and protein expression of NAT8L, 
respectively.  Gene expression of NAT8L and clinical outcomes were further 
investigated from publicly available databases from the cancer genomics atlas 
(TCGA) using www.cbioportal.org, and two previously published melanoma gene 
expression profiles.   Reverse Phase Protein Array (RPPA) and gene expression 
array were evaluated in HeyA8 ovarian cancer cell lines to investigate the protein 
and gene expression changes associated with NAT8L siRNA. In vitro and in vivo 
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experiments of NAT8L siRNA were investigated to evaluate its effects on cancer 
proliferation, apoptosis, cell cycle, and invasion/migration.     
Results:  A total of 313 metabolites were identified between these two groups, of 
which 172 were significantly altered (p<0.05) between HGSOC and normal ovary 
tissues.  NAA was one of the most significant alterations in HGSOC compared to 
the normal ovary with a greater than 28 fold elevation in ovarian cancer compared 
to the normal ovary (p=2.30E-11).  NAA levels in HGSOC were strongly correlated 
with its biosynthetic enzyme NAT8L gene expression levels (r=0.52, p<0.0001), and 
not with its degradation enzyme ASPA (r= -0.11, 0=0.30).  Patients with higher 
levels of NAA had worse overall survival (1295 days) compared to patients with low 
NAA levels (not reached) (p=0.038).  Two separate HGSOC gene expression 
cohorts revealed that high expression of NAT8L is associated with worse median 
overall survival in HGSOC (35 months, 40 months) compared to low NAT8L gene 
expression (45 months, 52 months) (p=0.03, p=0.005).  High NAT8L protein 
expression was associated with poor overall survival in ovarian cancer with 3.86 
years overall survival compared to 9.09 years with low NAT8L expression 
(p<0.001).  Furthermore, high NAT8L gene expression was found to have 
significantly worse overall survival in invasive breast, lung squamous, colon, uterine, 
melanoma and kidney renal cell cancers. 
HeyA8 and A2780 cell lines showed that NAT8L siRNA significantly 
increased total apoptosis compared to control (NT) siRNA by 38.53% (p<0.001) and 
37.85% (p<0.001), respectively.  HeyA8 cells treated with paclitaxel and NAT8L 
siRNA had a 29.83% increase in apoptosis compared to paclitaxel and NT siRNA 
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treated cells (p<0.001).  HEYA8 and A2780 cells treated with NAT8L siRNA had a 
significantly decreased cell proliferation by 23.65% (p<0.001) and 19.13% 
(p<0.001), respectively.  HEYA8 cells treated with NAT8L siRNA had an 8.4% 
increase in the number of cells with G1 phase (p<0.001), and an 11.65% decrease 
in the number cells in the S phase (p<0.001).  Knockdown of NAT8L in HEYA8 cells 
significantly decreased migration and invasion by 91% and 92%, respectively 
(p<0.001).  In HEYA8 orthotopic ovarian cancer mouse models, DOPC NAT8L 
siRNA had significantly decreased tumor burden by 69.17% (p<0.01), respectively.  
Furthermore, NAT8L siRNA + paclitaxel had significantly less tumor burden 
compared to NT siRNA (p<0.001), paclitaxel + NT siRNA (p=0.004), and NAT8L 
siRNA alone (p=0.032).  We observed similar effects in A2780, SKOV3 orthotopic 
ovarian cancer mouse models and orthotopic A375-SM melanoma mouse model.   
Genomic analysis of HEYA8 cells transfected with NAT8L siRNA compared 
to NT siRNA showed 1961 significantly different gene expression data (p<0.001).  
Hierarchical cluster analysis of RPPA from NAT8L siRNA and NT siRNA had 171 
significantly different protein expression data (p<0.05).  Computational network 
analysis (NetWalker) showed significant decreases in a large number of genes 
involved in mitosis and the M phase of the cell cycle, regulation of catabolic 
processes, and regulation of cell death being altered.    
Conclusion:  HGSOC metabolic profiling revealed highly altered metabolism 
compared to the normal ovary.  NAA is one of the most up-regulated metabolites in 
HGSOC.  High levels of NAA are associated with worse overall survival in HGSOC.  
Furthermore, high expression of its biosynthetic gene (NAT8L) is associated with 
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worse overall survival in HGSOC, invasive breast, lung squamous, colon, uterine, 
melanoma and renal cell cancers. Inhibiting NAA production decreases tumor 
growth, and tilts the cancer cell to a more catabolic steady state.  Therefore, our 
data indicate that targeting cancer’s NAA production maybe an effective therapeutic 
approach. 
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Background and Introduction 
Ovarian Cancer 
In the U.S., ovarian cancer is the fifth most common cause of cancer related 
deaths in women [1].  Approximately 22,280 women in the U.S. will be diagnosed, 
and 15,500 will die in one year of ovarian cancer [1].  Despite drug developments, 
ovarian cancer remains a high mortality cancer with diagnosis in late stage of 
disease and high tumor burden[2].  This high mortality is due the incidence of 
recurrence remaining high, and little has changed over 30 years [3,4]. 
  Treatment of primary ovarian cancer is a combination of tumor cytoreductive 
surgery and combination intravenous paclitaxel and carboplatin chemotherapy.  The 
role of surgery is important to extend overall survival with the ultimate goal of 
cytoreduction to no residual disease [5,6,7].    Patients with primary ovarian cancer 
have a 70-80% chemotherapy response rate; however, 40-50% will recur within two 
years.  Various chemotherapy route administration and dose adjustment have been 
attempted to improve outcomes.  For example, the administration of intraperitoneal 
(I.P.) chemotherapy has been shown to increase overall survival in patients with 
residual disease < 1 cm after surgery[8].  However, it remains controversial as 
direct comparison doses to intravenous chemotherapy is not available, and toxicity 
of I.P. remains a major issue[2].  Given the  poor survival and high recurrence of 
ovarian cancer with little improvement in patient outcomes despite cytotoxic drug 
developments over the years, the focus is turning on understand the tumor biology  
to identify new targets in therapy. 
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Cancer Metabolism 
 Altered metabolism is a well-established trait in many cancers, and is an 
emerging hallmark essential to cancer’s biology[9].  In order to better understand 
cancer metabolism, knowledge of unicellular microbes and proliferating cell in 
multicellular organisms can better illustrate the effect of environmental nutrition on 
cell functioning.  Under adequate nutrition availability, unicellular organisms such as 
microbes and proliferating cells in multicellular organisms have evolutionary 
pressure to replicate new cells.   These cells and unicellular organisms will uptake 
nutrients to provide carbon, nitrogen, and free energy to build new cells.  Glucose is 
the main nutrient metabolized by these cells, and through glycolysis will excrete 
carbons through lactate, ethanol, or other organic acids such as acetate or butyric 
acid[10].  In periods of nutrient deficiency or cell starvation, these cells will alter their 
metabolism to provide maximum amount of free energy for cell survival and 
temporarily halt cell replication[10].   
 In multicellular organisms, most cells are exposed to a constant supply of 
nutrients.  To prevent uncontrolled cell proliferation, these cells need growth factor 
stimulation of signaling receptors to stimulate uptake of nutrients.  Cancer cells 
overcome this by specific gene mutations that can alter receptor signaling 
pathways.  These pathways can be constitutively active allowing for constant 
nutrient uptake and metabolism that promote cell survival and growth[10].  
Therefore, altered cancer metabolism presents a promising approach to anti-cancer 
therapy development, and this has caused a resurgence of research revealing new 
metabolic pathways not seen in non-cancerous cells.      
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Glycolysis and Warburg Effect 
Under adequate oxygen supply, differentiated or non-proliferating cells 
metabolize glucose to CO2 by oxidizing pyruvate in the tricarboxylic acid cycle (TCA 
cycle).  This results in reduction of nicotinamide adenine dinucleotide (NADH).  
NADH fuels oxidative phosphorylation to maximize ATP production[10].  In 
anaerobic conditions, differentiated cells primarily rely on glycolysis for energy 
production, and therefore produce large amounts of lactate.  However, cancer cells, 
normal proliferating cells, and unicellular microbes rely heavily on glycolysis and 
produce large amounts of lactate even in the presence of adequate oxygen supply.  
This alteration of cell metabolism in cancer cells compared to non-cancerous cells 
was first reported by Otto Warburg in 1956[11].  This “Warburg effect” of high 
glucose consumption and high lactate production has clinically been taken 
advantage of by fluorodeoxyglucose positron emission tomography (FDG-PET) 
scans [12].   
The metabolism of one molecule of glucose using oxidative phosphorylation 
in the TCA cycle yields 36 ATP molecules, whereas under glycolysis, glucose only  
yields 2 ATPs[13].  So why do cancer cells rely heavily on glycolysis even when 
oxygenation is plentiful?  One explanation is that cancer cells are highly proliferative 
and require large amounts of biomass (lipids, amino acids, and nucleotides) to 
divide therefore these cells demand more than just ATP.  There is accumulating 
evidence that a “Supply-Based” model is more likely in cancer cells [14].  In this 
model, growth factor signaling directly increases nutrient uptake and alters 
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metabolism to maximize biomass production independent of ATP.  Thus, ATP is a 
secondary process in proliferating cancer cells.  An example of this is shown by Van 
Heiden et al. for the major cell membrane molecule, palmitate[10].   Palmitate 
synthesis requires 7 molecules of ATP, 16 carbons from 8 molecules of acetyl-coA, 
and 28 electrons from 14 molecules of reduced nicotinamide adenine dinucleotide 
phosphate (NADPH).  A glucose molecule can either provide 36 ATPs via oxidative 
phosphorylation, 30 ATPs and 2 molecules of NADPH though pentose phosphate 
pathway, or 6 carbons in the form of acetyl-CoA for macromolecular synthesis. 
Therefore, proliferating cells demands for glucose are inclined more for NADPH and 
acetyl-CoA production for palmitate synthesis, and not ATP from oxidative 
phosphorylation.  Furthermore, the commitment of glucose into maximal ATP 
production by oxidative phosphorylation would increase ATP/ADP ratio therefore 
inhibiting NADPH and acetyl-CoA production.  Therefore, glucose consumption in 
proliferating and cancer cells is more so needed for acetyl-CoA production for lipid 
synthesis, diversion to PPP for ribose production for nucleotide synthesis, and 
glycolytic intermediates for non-essential amino acid production.  
Mitochondria and cancer 
  The mitochondria genome includes one to two thousand nuclear DNA gene, 
and thousands of copies of mitochondrial DNA inside the mitochondria[15].  The 
mitochondrial DNA contains the 13 most important genes for oxidative 
phosphorylation while the nuclear DNA contains the rest including genes for 
mitochondrial metabolic regulation[15].  The mitochondria has many essential 
cellular functions and regulates energy production, oxidation-reduction (redox) 
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status, cytoplasmic calcium levels, reactive oxygen species (ROS) production, 
biosynthetic precursors such as acetyl-CoA, and apoptosis[15].  It is clear that many 
cancer cells do not have dysfunctional mitochondria as a well-functioning 
mitochondrion is needed for cell viability and growth [16,17].  Mitochondrial DNA 
mutations can alter cell metabolism and enhance tumorigenesis by impairing 
oxidative phosphorylation and adapting the cell’s bioenergetics state for 
proliferation[18]. Mutations in mitochondrial nuclear DNA genes can also contribute 
to tumorigenicity.  Mutations in succinate dehydrogenase (SDH), fumurate 
hydratase (FH), and IDH1 and IDH2 can increase levels of succinate, fumurate, and 
R-2-hydroxyglutarate [(R)-2-HG][19,20,21].  This can inhibit various alpha-
ketoglutarate dioxygenase levels and activate NRF2 response leading to increased 
tumorigenicity [20,22]. 
Altered cancer metabolism can increase ROS produced by mitochondria.  
Mitochondrial ROS is a potent mitogen, and if apoptosis is inhibited, high ROS can 
cause neoplastic transformation [23,24].  Furthermore mitochondrial ROS can 
stabilize hypoxia inducible factors (HIF), nuclear factor kappa-B (NF-Kβ), and FOS-
JUN transcription factors thereby increasing cell proliferation [15,25].   Cancer cell 
ROS can also affect the tumor microenvironment whereby it inactivates caveolin-1 
in the surrounding stromal fibroblasts.  This increases fibroblast mitophagy reducing 
its mitochondrial function, and increases fibroblast lactate production.  The over 
production of lactate in fibroblasts can fuel cancer cells to aid in proliferation and 
growth.  [26] 
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Lipogenesis in cancer 
Most non-cancerous mammalian cells get lipids from the blood stream, and 
de novo lipogenesis occurs mainly in liver, adipocytes, and lactating breasts[27].  
Cancer cells can synthesize lipids similar to embryonic cells by reactivating de novo 
lipogenesis [28,29].  The increase in lipid synthesis has important consequences to 
cancer cell survival and growth.   One consequence of lipogenesis is for the 
massive biomass accumulation.  In fact, inhibition of lipid synthesis has been shown 
to decrease cancer cell proliferation and tumor growth [30,31,32,33].  Fatty acids 
contribute to phospholipids (phosphotidylcholine, phosphotidylethalamine) for cell 
membrane synthesis, and phospholipids are associated with poor survival in several 
cancers [34,35].   
There is evidence that lipid synthesis confers resistance in cancer cells to 
oxidative stress.  Cancer cells have high rates of saturated and mono-unsaturated 
fatty acid synthesis, and this has been shown to reduce cell death induced by 
oxidative stress or chemotherapy agents[36].  Inhibition of lipid synthesis may seem 
promising to combine with chemotherapy agents to improve the efficacy of its 
cytotoxicity.   
Increased lipid synthesis may also confer cell resistance to the effects of 
energy stress.  Some tumors rely on lipid oxidation as a source of energy 
production by using mitochondrial beta-oxidation to produce ATP via OXPHOS 
[37,38].  Activation of beta-oxidation seems to be needed for cancer cell viability 
during times of energy stress [39,40].   
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The regulation of lipid synthesis is mainly done by Sterol Regulatory Element 
Binding Transcription Factor (SREBPs)[41].  There are three isoforms that regulate 
lipogenesis:  SREBP1a, SREBP1c, and SREBP2[42].  SREBP1a is most abundant 
in cultured cells [43].  Although there are overlaps, SREBP1s mainly regulate fatty 
acid, phospholipid, and triaceylglyceride synthesis, and SREBP2 main regulates 
cholesterol synthesis [41].  Cancer tissues show elevated level of SREBPs[27].  
Regulation of SREBPs can be positively regulated by PI3K/AKT/mTOR, loss of 
retinoblastoma (Rb), and mutant p53 [44,45,46].  Negative regulation of SREBPs is 
seen with high phosphotidlycholine or AMPK activity [47,48].   
Amino acids and Cancer metabolism 
Amino acids (AA) are carbon molecules that contain amino and acid groups 
that have variable side chains giving them different biochemical functions [49].  
There are 300 known amino acids, but only 20 of them serve as building blocks for 
proteins(Table 1) [49].  Amino acids such as ornithine, citrulline, homocysteine, 
taurine, and β-alanine have major roles in cell metabolism [50,51,52,53].  Important 
functions of AA catabolism leads to metabolites with important biologic functions 
such as ammonia, carbon dioxide, long and short-chain fatty acids, glucose, ketone 
bodies, nitric oxide, urea, uric acid, polyamines, and nitrogenous substances[49].    
In addition AA can regulate gene expression and proteins signaling, synthesize 
hormones and low-molecular weight nitrogenous substances, and regulate 
metabolic pathways for growth and survival.    
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Table 1.  Twenty protein building amino acids 
Essential amino acids Non-essential amino acids 
Arginine Alanine 
Histidine Asparagine 
Isoleucine Aspartate 
Leucine Cysteine 
Lysine Glutamate 
Methionine Glutamine 
Phenylalanine Glycine 
Threonine Proline 
Tryptophan Serine 
Valine Tyrosine 
 
AA can regulate gene expression at transcription, translation, and post-
translational protein modifications [49].  For example, methionine, glycine, serine 
and histidine can methylate proteins and DNA, thus regulating gene and protein 
signaling [49].  Glutamine, arginine, and leucine can stimulate mTOR1 in a cell 
specific manner therefore increasing its anabolic activity of protein synthesis and 
inhibiting autophagy [54,55].   
     AA can be precursors for low-molecular weight hormones and neurotransmitters.  
Tyrosine or phenylalanine can be synthesized into epinephrine, norepinephrine, 
dopamine, and thyroid hormones [49].  Tryptophan is a precursor for serotonin and 
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melatonin.  Glutamate is the precursor for GABA [49].  Furthermore, high doses of 
oral of intravenous AA can stimulate hormones from endocrine cells.  Arginine, 
glutamine, and leucine can stimulate insulin, growth hormone, prolactin, glucagon, 
progesterone, and placental lactogen [56,57].   
   Another important function of AA is regulating key metabolic pathways in cells.  
For example, glutamate and aspartate mediate transfer of reducing equivalents 
across the mitochondrial membrane via the malate-aspartate shuttle which affects 
glycolysis and cell redox status.  The net result of the malate-aspartate shuttle is 
that NADH is transported from the cytosol into the mitochondria generating 3 ATP 
molecules [58].  Another example of metabolic regulation by AA is with arginine.  
Arginine increases expression of AMPK and peroxisome proliferator-activated 
receptor γ co-activator 1-α (PPAR) proteins which has been shown to affect 
mitochondrial energy status and rat fat mass [59].   
  Glutamine is one of the highest nutrients to be consumed by cancer cells.  
Glutamine is a non-essential amino acid because humans are able to synthesize it 
from glutamate and ammonia via the enzyme glutamine synthetase(GS)[13].  
However, not all human tissues have GS therefore these tissues rely on glutamine 
uptake from tissues that are able to synthesize glutamine.  Glutamine can be used 
in cells for protein synthesis, nucleotide synthesis, and glucosamine production[60]. 
Cells that are driven to growth by the oncogene MYC are particularly sensitive to 
glutamine availability.  MYC driven cells will undergo apoptosis by failing 
anaplerosis from glutamine derived substrates [61].     
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Glutamine together with glucose provides most of the carbon and nitrogen 
needed for cell replication [62].  In glioblastoma cells, approximately 60% of 
glutamine and 90% of glucose can produce lactate and alanine waste.  Glutamine 
provides TCA intermediate alpha-ketoglutarate for anaplerosis which promotes 
NADPH production via malic enzyme. Pyruvate is synthesized in this reaction which 
is then converted to lactate by lactate dehydrogenase [62].  Therefore, the excess 
lactate production seen in the “Warburg effect” is not only a consequence of 
glucose/glycolysis, but also of the glutatmine/glutaminolysis pathway.    
Although glucose is the major lipogenic precursor in cancer cells, glutamine 
can also provide carbons for lipid synthesis.  14C labeling of glutamine showed that 
25% fatty acyl molecules in glioblastoma cells were derived from glutamine.  
Furthermore, glutamine analplerosis provides oxaloacetate substrate that combines 
with glucose derived acetyl-coA for citrate production via citrate synthetatase[62].  
However, some cancer cells with mutations in TCA cycle enzymes or electron 
transport chain have defective mitochondrial functioning for lipid synthesis.  These 
cancer cells rely on glutamine dependent reductive carboxylation for citrate 
formation.  This pathway relies on cytoplasmic and mitochondria isocitrate 
dehydrogenase enzyme (IDH), therefore rendering glutamine as the major source 
for acetyl-coA production in lipid synthesis [63].    
   There is emerging evidence for the role of other amino acids and their role in 
cancer progression.  For example, inhibiting glycine uptake and its mitochondrial 
biosynthesis impairs proliferation in cancer cells [64].  Prostate cancer cells have 
high levels of the amino acid sarcosine (a glycine derivative), and high levels of 
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sarcosine lead to cancer progression and metastases [65].  Functional genomics 
has shown that serine synthesis is essential for breast cancer carcinogenesis [66].  
Inhibition of the isoform M2 pyruvate kinase (PKM2) leads to accumulation of 
glycolytic intermediates into the serine synthesis pathway therefore maintains 
mTOR1 activity [67].    Furthermore, serine starvation in p53 deficient cells resulted 
in oxidative stress, reduced cell viability and increased cell proliferation [68]. 
Besides glucose, glutamine is also another nutrient heavily consumed by 
cancer cells.  Glutamine is a non-essential amino acid because humans are able to 
synthesize it from glutamate and ammonia via the enzyme glutamine 
synthetase(GS)[13].  However, not all human tissues have GS therefore these 
tissues rely on glutamine uptake from tissues that are able to synthesize glutamine.  
Glutamine can be used in cells for protein synthesis, nucleotide synthesis, and 
glucosamine production[60]. Cells that are driven to growth by the oncogene MYC 
are particularly sensitive to glutamine availability.  MYC driven cells will undergo 
apoptosis by failing anaplerosis from glutamine derived substrates [61].     
Glutamine together with glucose provides most of the carbon and nitrogen 
needed for cell replication [62].  In glioblastoma cells, approximately 60% of 
glutamine and 90% of glucose can produce lactate and alanine waste.  Glutamine 
provides TCA intermediate alpha-ketoglutarate for anaplerosis which promotes 
NADPH production via malic enzyme. Pyruvate is synthesized in this reaction which 
is then converted to lactate by lactate dehydrogenase [62].  Therefore, the excess 
lactate production seen in the “Warburg effect” is not only a consequence of 
glucose/glycolysis, but also of the glutatmine/glutaminolysis pathway.    
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Although glucose is the major lipogenic precursor in cancer cells, glutamine 
can also provide carbons for lipid synthesis.  14C labeling of glutamine showed that 
25% fatty acyl molecules in glioblastoma cells were derived from glutamine.  
Furthermore, glutamine analplerosis provides oxaloacetate substrate that combines 
with glucose derived acetyl-coA for citrate production via citrate synthase [62].  
However, some cancer cells with mutations in TCA cycle enzymes or electron 
transport chain have defective mitochondrial functioning for lipid synthesis.  These 
cancer cells rely on glutamine dependent reductive carboxylation for citrate 
formation.  This pathway relies on cytoplasmic and mitochondria isocitrate 
dehydrogenase enzyme (IDH), therefore rendering glutamine as the major source 
for acetyl-coA production in lipid synthesis [63]. 
AMPK and cell metabolism 
 One of the key metabolic regulators in eukaryotic cells is AMP-activated 
protein kinase (AMPK)[69].  Ultimately, the role of AMPK is to balance the ratio of 
ATP consumption and ATP generation.  AMPK promotes cell catabolism to 
generate more ATP, and inhibits anabolic pathways[69].    AMPK can be activated 
by lowering of intracellular ATP; AMP or ADP can directly bind to its regulatory 
subunit causing a conformational change that protects its activating phosphorylation 
[70,71].  The major phosphorylation mechanism of AMPK is by the threonine/serine 
kinase Liver Kinase B1 (LKB1) at Thr172 [72,73].  AMPK can also be 
phosphorylated at Thr 172 by calcium flux, independent of LKB1, by CAMKK2 
(CAMKKβ) kinase [74].  The majority of AMPK regulation in cell are by LKB1, 
however, CAMKK2 appears to be major AMPK regulators in T-cells and neurons 
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[75,76]. TAK1of the MAPKKK family can also activate AMPK by phosphorylating 
Thr172 [77].  Additional controls of AMPK regulation are currently unknown.   
 In mammalian cells, AMPK can be activated by a variety of cell stresses and 
variety of drugs which increase cellular levels of AMP, ADP, or calcium [78]. 
Metformin, the type 2 diabetes drug, can activate AMPK in a LKB1 dependent 
manner[79].   Metformin indirectly causes AMPK activation by inhibiting Complex I 
of the respiratory chain leading to lower ATP levels[80,81].  The AMPK agonist 
AICAR is a precursor to ZMP which mimics AMP, and also indirectly activates 
AMPK[82].  The chemotherapy drug pemetrexed can also result in elevated ZMP 
therefore activating AMPK [83].   
 There is emerging evidence that AMPK can be activated independent of 
AMP, ADP, or calcium.  In cultured cells, AMPK is activated by reactive oxygen 
species (ROS).  The mechanism of action is unclear, but it has been proposed to 
involve inhibition of mitochondrial ATP synthesis[80], oxidation of two conserved 
cysteine residues in the AMPK alpha subunit[84], or by the protein ataxia 
telangiectasia (ATM) which can phosphorylate LKB1[85].  Genotoxic agents such as 
etoposide, doxorubicin, and ionizing radiation can also activate AMPK, although the 
mechanism is not clear [86,87,88]. 
 AMPK coordinates PI3K/AKT/mTOR pathway to control cell growth and 
autophagy.  For example, mTORC1 is tightly regulated by AMPK.   AMPK can 
either phosphorylated the tumor suppressor TSC2 on serine 1387 or directly 
phosphorylate Raptor (regulator associated protein of mTOR) blocking the ability of 
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mTORC1 kinase to phosphorylate its substrates [89,90].  The autophagy 
components ULK1 can be directly activated by AMPK or by mTORC1[91,92] .  
Autophagy is activated to replenish metabolites and nutrients in times of low energy 
state.  AMPK can trigger destruction of defective mitochondria though ULK1 
dependent mitophagy and trigger mitochondrial biogenesis though PGC-1-alpha 
transcription[69].  In hematopoietic stem cells, genetic knockout of LKB1 or AMPK 
catalytic subunits caused a significant rise in defective mitochondria[93].  Therefore, 
AMPK is a key regulator of mitochondrial homeostasis. 
AMPK can alter cellular metabolism by directly regulating metabolic enzymes or 
by altering transcription.  AMPK is a key regulator of acetyl-coA carboxylase (ACC) 
and HMG-coA reductase which are rate limiting steps for fatty acid and sterol 
synthesis, respectively[94,95].  In fat cells, AMPK directly phosphorylates lipases 
such as hormone sensitive lipase and adipocyte triglyceride lipase (ATGL)[96,97].  
AMPK can regulate glucose uptake of cells by playing a key role in GLUT4 
endocytic trafficking [98].   AMPK can phosphorylate a number of transcription 
factors, coactivators, acetyltransferase p300, histone deacetylases, and histones 
that can alter cell metabolism[69].  One example is the lipogenic transcription factor 
(SREBP1) by phosphorylating a conserved serine site suppressing its activation.  
SREBP1 induces expression of ACC and FASN to promote de novo lipogenesis, 
and tumor growth [99,100].  AMPK can negatively regulate cAMP-regulated 
transcriptional co-activators (CRTCs) and histone deacetylates(HDACs) [101,102].  
Negative regulations of CRTCs have recently been shown to prolong lifespan in C. 
elegans opening up a new potential of biological functions for these co-activators 
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[101].  AMPK phosphorylation of HDACs in the liver can translocate to the nucleus 
to deaceytlate FOXO family transcription factors and regulate glucose homeostasis 
in the liver[103].   Increased expression of CRTCs and HDACs can promote tumor 
progression and growth [104,105,106].   
P53 and tumor metabolism 
Findings from The Cancer Genome Atlas (TCGA) showed that many high 
grade epithelial ovarian cancers have p53 mutations (96%), a high rate of somatic 
mutations with few recurrent mutations, and high copy number alterations[107].  
P53 is a tumor suppressor by two mechanisms: 1.) regulating repair and survival of 
damaged cells 2.) Discarding damaged cells that cannot be repaired through 
apoptosis or autophagy.  Activation of p53 from DNA damage leads to G1 cell cycle 
arrest and DNA repair activation.  This mechanism allows to cells to resume normal 
cell cycle functioning and the genomic integrity is maintained.  To remove damaged 
cells that can’t be repaired, p53 can activate pro-apoptotic genes such as Bax, 
Noxa, and Puma. In addition to cell survival and death, p53 can also influence 
cellular metabolism. 
   The evidence of p53 regulation of glycolysis is complex and unclear.  
Emerging evidence is revealing p53 a major negative regulator of glycolysis 
mediated by p53 transcriptional activation of TP53-induced glycolysis and apoptosis 
regulator (TIGAR).  TIGAR dephosphorylates fructose-2, 6-bisphosphate (F2-6P) 
and lowers its cellular levels.  F2-6p is a potent activator of the glycolytic rate 
limiting enzyme 6-phosphofructo-1-kinase (PFK-1), therefore p53 inhibits glycolysis 
through this mechanism [108].  Also, p53 can down-regulate phosphoglycerate 
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mutase (PGM) which converts 3-phosphoglycerate to 2-phosphoglycerate in 
glycolysis, thus inhibiting glycolytic flux.  On the other hand, some studies are 
showing that p53 can activate glycolysis by stimulating type II hexokinase promoter 
gene expression, and this activation leads to increased tumor survival[109,110].  
Clearly, further studies are needed to clarify p53’s role in glycolysis. 
  P53 can stimulate mitochondrial oxidative respiration by activating several 
key components of the electron transport chain in cancer cell.  Furthermore, p53 
can increase the TCA cycle rate by activating glutaminase 2 (GLS2)[111,112].  
GLS2 is a mitochondrial protein that hydrolyzes glutamine to glutamate, and 
deamination of glutamate leads to alpha-ketoglutarate synthesis.  Furthermore, p53 
knock-out mice display impaired mitochondria respiration [112].   
 De novo lipogenesis has also been shown to be regulated by p53.  AMPK 
expression is up-regulated by p53 and this result in increased inactivation of the 
lipid rate limiting enzyme ACC [102].  P53 also regulated biomass production by 
inactivating glucose-6-phosphate dehydrogenase resulting in suppression of 
pentose phosphate pathway and decreased NADPH production [113].  As stated 
before, NADPH is critical for lipogenesis in proliferating cells.  On the other hand, 
emerging evidence is developing that in times of energy stress, p53 can up-regulate 
fatty acid oxidation to produce ATP and NADPH further promoting cell survival and 
resistance to the metabolic stress[114].  For example, a new p53 target GAMT has 
been identified which is involved in the creatine pathway.   GAMT is involved in p53 
induced apoptosis under genotoxic stress.  However, under glucose deprivation and 
energy stress, p53 dependent up-regulation of GAMT induces fatty acid oxidation 
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increasing cell survival [115].  This complicated dual role of p53 in cancer 
metabolism suggests that its role may be tissue and/or cancer specific.  Further 
understanding of various cancer types and the role of p53 in regulating its 
mechanism are needed.   
Targeting Cancer Metabolism 
 It is important to note that targeting cancer metabolism is not a new approach 
in cancer therapy history.  Sidney Farber noticed that adding folic acid to leukemic 
cells caused an increase in cancer growth[116].  This discovery lead to the 
development of the first folate analogue drug aminopterin which lead to the first 
remission of Acute Lymphoblastic Leukemia[117]. Another folate analogue, 
methotrexate lead to the first cure of solid tumors when administered to 
choriocarcinoma patients[118].     
The emerging studies of altered cancer metabolism have revealed the high 
consumption of various nutrients, the increased biosynthetic pathways, and the 
oncogenic signaling driving these changes are paving the way for novel approaches 
to anti-cancer therapy development.  For example, circulating levels of insulin and 
insulin growth factor (IGF) seen in obesity and diabetes promote cancer progression 
by activating cancer growth signaling [119,120,121].  Lowering blood glucose levels 
is associated with improving cancer outcomes [121].  The diabetic drug Metformin is 
being explored as an agent that can improve cancer outcomes.  Metformin lowers 
blood glucose by inhibiting mitochondrial complex I in liver which decreases ATP 
production [79,119].  This up-regulates AMPK signaling, which inhibits 
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gluconeogenesis, effectively lowering blood glucose levels and increasing insulin 
sensitivity to lower circulating levels of insulin [79].  
Despite driver mutations causing cancer growth and progression, there are 
no effective treatments against these mutations.  Targeting metabolic enzymes 
seems a promising approach to disrupt these driver mutation effects.  For example 
k-RAS and MYC rely on glucose and glutamine uptake for cell growth and survival, 
respectively [61,122].  Disrupting glucose or glutamine uptake or their pathway 
molecules in these cells can be an important approach to stopping its growth 
mechanism.  Cytoxic chemotherapy can also disrupt glucose uptake, therefore 
synthetic lethality approaches by combining chemotherapy and metabolic enzyme 
drug targets would seem like a promising approach[119].  
Ovarian cancer metabolism 
 Recent investigation of ovarian cancer revealed a shift in cancer metabolism 
paradigm, Nieman et al. showed that ovarian cancer cells behave like parasites to 
the surrounding host cells by inducing catabolic processes in the adipocytes and 
tumor stroma.  Ovarian cancer cells were homed to the host cells by cytokines such 
as IL-8, and would increase catabolic processes such as aerobic glycolysis; 
mitophagy, autophagy, and lipolysis in the host cells.   Because of this processes, 
cancer cells were able to extract nutrients such as lactate, fatty acids, glutamine, 
and ketones to fuel the mitochondria and promote growth and metastasis [123].  
Therefore, ovarian cancer cells up-regulated their oxidative phosphorylation and 
beta-oxidation to use these substrates for ATP production.  Interestingly, the 
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authors saw that SKOV3ip1 cells co-cultured with adipocytes had up-regulated 
AMPK, inhibition of ACC, and up-regulation of beta-oxidation in cancer cells.   
RPPA analysis of primary ovarian tumors compared to omental metastasis tumor 
revealed that the metastatic tumors had greater ACC phosphorylation.  This was a 
surprising finding given the many other results show that show up-regulation of 
AMPK and inhibition of ACC to lead to decreased tumor 
growth[33,124,125,126,127].     
Along with fatty acid metabolism, ovarian cancers have increased choline-
containing metabolites [35].  These include phosphotidylcholine, phosphocholine, 
glycerophosphocholine, and choline is important for many cell functions including 
proliferation and cell membrane synthesis.  Mechanisms behind these elevations 
include choline transport, choline mediated choline kinase phosphorylation, and 
activation of phosphotidylcholine phospholipases. Inhibition of these 
phosphotidycholine metabolic pathways can inhibit tumor growth, and a novel 
choline kinase inhibitor Mn58b, has shown to inhibit growth in carcinoma models 
[128]. 
There has been one attempt at a large scale metabolic profile in ovarian 
cancer, Denkert C. et al. profiled 66 ovarian cancer tissues and 9 borderline tissues 
using GC/mass spectrometry.  They detected 291 metabolites, but were only able to 
identify 114 (39%) of these metabolites.  Using a threshold of p<0.01, they were 
able to identify 51 metabolites that differed from ovarian cancer and borderline 
tumors.  An increase in glycerolipid, purine and pyrimidine, and energy metabolism 
were noted to be higher in ovarian cancer.  Interestingly, several fatty acids and 
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lactate were higher in borderline tumors.  A major limitation of the study was that the 
ovarian cancer samples included 25% non-serous tumors, and 43% of the ovarian 
cancer tumors were not high grade tumors. 
Oncometabolites 
 The recent resurgence of cancer metabolism studies has identified dysregulated 
metabolic pathways that produce novel oncometabolites in cancer.  Genome-wide 
sequencing of glioblastoma multiforme (GBM) or WHO III and III astrocytoma and 
oligodendroglioma revealed that the majority of these tumors harbor an IDH1 or 
IDH2 mutation[129,130].  The two initial studies showed that IDH1 and IDH2 
mutation in these patients doubled the median overall survival compared to the wild 
type IDH1/2 patients [129,130].  These mutations are not only prevalent in high 
grade gliomas, but also in acute myeloid leukemia [131]. These mutations cause the 
loss of the cell’s ability to convert α-ketoglutarate to isocitrate when the mutant IDH 
protein forms a heterodimer with the wild type IDH protein therefore inactivating the 
physiologic IDH enzyme function.  When the IDH mutant protein forms a homodimer 
protein,  these mutations gain the ability to create the metabolite called (R)-2-
hydroxyglutarate (2HG) [21,131] from α-ketoglutarate and glutamate which can lead 
to DNA hyper methylation [132,133,134].  Furthermore, studies of 2HG are 
identifying that 2HG has tumorigenic properties instead of the tumor suppressive 
role.  Recently, high serum levels of 2HG are associated with worse overall survival 
in AML [135].  
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   In a metabolic profile of human oligodendroglioma cells (HOG), Reitman et al 
evaluated the effects of isocitrate dehydrogenase 1(IDH1-R132) and 2 (IDH2-R172) 
mutations.  One of the most striking findings in their study was that the levels of N-
acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) in IDH1-R132 and 
IDH2-R172 cells compared with wild type IDH1 and IDH2 cells were significantly 
decreased. No pathogenesis as result of low NAA or NAAG was investigated in this 
study; therefore the role of NAA and NAAG is unclear in this setting. The authors 
speculated that since acetyl CoA or free amino acid levels were not decreased 
between the wild type and IDH mutated cells in this the HOG cells, the decreased 
NAA can be a result of low NAT8L expression or high ASPA expression.  In a 
separate study of non-invasive detection of 2HG in WHO grade 2 and 3 glioma 
patients using proton magnetic resonance spectroscopy (MRS) showed with high 
sensitivity and specificity in IDH1 and IDH2 mutated gliomas had higher 2HG and 
lower NAA peaks compared to wild type IDHI/2 gliomas.  Therefore, both IDH 
mutation metabolic studies show that the wild type IDH1/2 gliomas lead to low 2HG 
and higher NAA levels compared to the mutant IDH1/2 gliomas.  With that said, the 
mechanism of IDH mutation decreasing NAA levels is currently unclear and further 
work is needed to provide insight into the function of NAA and 2HG in gliomas.    
The neuron specific metabolite NAA 
 NAA is the N-acetylated amino acid aspartic acid via the amine nitrogen 
group.  Acetylation is the transfer of an acetyl group from acetyl-coA to another 
molecule; in this case the amino acid aspartic acid accepts the acetyl group to form 
NAA.   The molecular weight of this compound is 175 Daltons in its ionic form.  NAA 
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biosynthesis occurs in neurons by the catalysis of the enzyme N-acetylaspartate 
synthetase (NAT8L)[136,137].  The NAA metabolic pathway in the neuron illustrated 
is discussed below (Figure 1)[138].   
.   
Figure 1.  Schematic presentation of NAA metabolism [138].NAA is 
synthesized in the neuron via the enzyme NAT8L by acetyl-coA and aspartate.  
NAA and glutamate form NAAG in an ATP dependent manner via the enzyme 
NAAGS.  NAAG is transported out of the neuron by an uknown mechanism to the 
extra-neuronal space (ECF).  NAAG is hydrolyzed into NAA and glutamate in the 
ECF.  Glutamate binds to the metabotropic glutamate receptor 3 (mGLuR3) to 
activate the glutamatergic neurotransmission process.   NAA is taken up by 
oligodendrocytes by sodium-dependent dicarboxylate transporter (NaDC3).  Inside 
oligodendrocytes, NAA is metabolized by aspartoacyclase (ASPA) into aspartate 
and acetate.  Acetate is proposed to be used for the myelin lipid synthesis.  
  
The sources for acetyl-coA for NAA in the brain of developing rats are pyruvate 
from glycolysis and 3-hydroxybutyrate (a ketone body).  The aspartate arises from 
aspartate transamination (AST) by using the substrates glutamate and oxaloacetate 
forming aspartate and alpha-ketoglutarate [139].  The NAT8L enzyme has only 
been localized in the neuronal mitochondria and microsomes (likely endoplasmic 
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reticulum) [136,140,141].  NAA production is faster under high respiration energy 
state than in low respiration energy state[139]. NAA production can be stimulated by 
ADP, and inhibited by ATP production [142].      
NAA is a major form of aspartic acid in the brain, and NAA concentrations in the 
brain are on average 3-8 mM [143], making it one of the most distinct signals that is 
prominent by brain magnetic resonance spectroscopy (MRS)[144,145,146]  [147].   
After its synthesis, NAA can bind with glutamate to form NAAG by the ATP 
dependent enzyme NAAG synthetase [138].  NAAG is transported out of neuron 
into the ECF where it can be hydrolyzed back into NAA and glutamate by the 
membrane bound enzyme Glutamate Carboxypeptidase II (GCP-II) or CGP-III.  
Genes encoding for these proteins are FOLH1 and NAALAD2, respectively.  The 
glutamate binds to astrocyte Glu metabotropic receptor 3 (GRM3), and is taken up 
to form glutamine[147].  Furthermore, GRM3 activation can signal endothelial cells 
to form new capillaries allowing for transport of glucose and oxygen to 
neurons[147].  NAA is targeted towards oligodendrocytes [140], where it is taken up 
by the sodium ion transporter NaDC3.   
Uptake of NAA allows for its degradation into acetate and aspartate by the 
enzyme aspartoacyclase (ASPA) [148].  ASPA is zinc containing carboxypeptidase 
enzyme, which deacetylates NAA [149]. ASPA is present in several tissues such as 
CNS, liver, and kidney in the developing rat [150].  The mammalian neurons do not 
contain ASPA, therefore oligodendrocyte are where the NAA are transported to be 
metabolized in the CNS [151]. 
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The primary function of NAA remains elusive as most studies have focused on 
MRS studies compared to the biochemistry of NAA.  Furthermore, almost all studies 
are based on the mammalian brain.  It is proposed that NAA can function as 
alternative source of acetate for lipid synthesis by transporting into oligodendrocytes 
where it is broken down into acetate by ASPA for lipid synthesis [152,153,154,155]. 
Alternatively, NAA has been proposed to act as an osmotic regulator by transporting 
water bound to NAA into ECF [156].   
NAA has also been linked to ATP production, and proposed to be involved in 
analplerosis [38,139,142].  This is based on the theory that depletion of aspartate 
from the mitochondria would promote the kinetics of aspartate transaminase (AST) 
towards aspartic acid and alpha-ketoglutarate production [148,157].  It is reasonable 
to assume that all of these functions can co-exist as the consequences of NAA 
biosynthesis and metabolism, and further research would help clarify NAA’s biologic 
role.  
More evidence of its biological role are highlighted by two inborn errors of 
metabolism diseases which involve disruption of the NAA metabolic pathway.  The 
first is called hypoacetylaspartia characterized by the inability to biosynthesize NAA 
by NAT8L.  There has been one documented case in history of a patient with 
hypoacetylaspartia.  This patient suffered from severe mental retardation, ataxia, 
microcephaly, and seizures[158].  This patient was found to have homozygous 
mutation of NAT8L [137].  In a single reported study of NAT8L knockout mice study 
the focus was mainly on the social behavior of mice which showed decreased social 
interaction and greater anxiety like behaviors in homozygous deleted NAT8L [159]; 
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no other histological or MRS detection of NAA was reported in this study limiting 
any generalizability to the human condition.   
The second inborn error of metabolism disease with abnormal NAA levels is 
Canavan disease.  Canavan disease is characterized by a lack of ASPA activity 
which leads to NAA accumulation.  Clinically,  patients with this disease display 
macrocephaly, severe cognitive and motor delay, seizures, and death by the third 
decade of life [160].   The pathologic hallmark of Canavan disease is 
dysmyleination, intramyelinic edema , and central white matter vacuoles[160].  The 
knockout mice studies for ASPA have recapitulated the biologic effects seen in 
human Canavan disease.   Homozygous (-/-) ASPA mice display failure to thrive, 
macrocephaly, neurologic impairments such as tremors, abnormal gait, lethargy, 
pain insensitivity, and some developed seizures by 6 months of age.  MRS of the -/- 
ASPA mice showed abnormally high levels of NAA compared to the wild type mice, 
and histopathologic evaluation of the brain showed features similar to those seen in 
Canavan disease [161].   
NAA has recently been detected outside of the CNS [65,162,163,164].  
Aspiration from ovarian tumor cysts (OTC) has been linked to be significantly higher 
in the serous histology type benign, borderline, and malignant tumors [163,164], 
and there was no difference between NAA levels in OTC between the malignant, 
borderline, or benign serous tumors.  The range of OTC NAA concentrations in 
serous tumors have been reported between 5-187 µM [163,164,165].  However,  
higher NAA concentrations in ovarian cyst fluid  of malignant serous ovarian 
cancers have been found to be associated with advanced stage disease (Stage III 
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and IV)[163].  The concentrations of NAA levels in OTC have also been found to be 
relatively similar to the concentration present in malignant ascites[163].  These 
findings suggest that NAA in cyst and ascites fluid are associated with higher stage 
disease, and that NAA levels may be associated with worsening outcomes.  
In a small study, the metabolome of normal human ovaries, primary ovarian 
adenocarcinomas (POC) and metastatic omental ovarian cancer (MOC) tumors 
were profiled by LC and GC mass spectrometry.   NAA and NAAG levels were 
elevated by 3.5 and 2.2 fold, respectively, in POC compared to the normal ovary.  
NAA and NAAG were further elevated by 85.6 and 8.5 fold, respectively, in MOC 
compared to the normal ovary[162].  This indicates that NAA levels are even much 
higher in the metastatic tumors compared to the primary ovarian cancer site, and 
suggests that its accumulation may have a role in ovarian cancer pathogenesis.   
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Hypothesis and specific aims: 
Hypothesis #1:  Metabolic profiling of ovarian cancer compared to the normal 
ovary will identify tumor promoting metabolites   
Specific Aim:  Identify the most up-regulated metabolite in ovarian cancer 
compared to the normal ovary in human patients and determine the consequences 
to tumor growth when its production is inhibited   
Hypothesis #2:  High levels of NAA are associated with worse outcomes in 
ovarian cancer 
• Specific Aim:  Determine the clinical consequences of alterations in 
the NAA pathway in ovarian cancer 
Hypothesis #3:  Decreasing NAA production will decrease tumor growth and 
progression 
• Specific Aim: Examine the biological effects of inhibiting NAA 
production by siRNA NAT8L in ovarian cancer cell proliferation, 
survival, and invasion using in vitro and in vivo assays 
 
 
 
 
 
 28 
 
 
Methods 
Clinical Analysis 
 After IRB approval was obtained, patients were identified at the University of 
Texas at M.D. Anderson Cancer Center (MDACC) and the University of Iowa who 
were diagnosed with ovarian, primary peritoneal, or fallopian tube carcinoma.  
Patients were excluded if they did not receive primary therapy at the institution of 
record or did not have routine follow-up at that institution.  All patients were treated 
by surgical cytoreduction performed by a gynecologic oncologist in addition to 
adjuvant or neoadjuvant taxane- and/or platinum-based chemotherapy. Surgical 
staging was performed according to International Federation of Gynecology and 
Obstetrics guidelines. All treatments were administered at the institution of record. 
Specimens were reviewed by a gynecological pathologist at the institution of record. 
Clinical data collected included patient demographics, tumor characteristics, details 
of treatment, as well as outcomes data such as progression-free interval and overall 
survival. Optimal cytoreduction was defined by convention as residual disease less 
than 1 cm as reported by the surgeon of record.  Tissue samples were obtained at 
the time of primary evaluation surgery.  Patients who were known to be alive and/or 
progression-free at the time of last contact were censored accordingly.  Kaplan-
Meier survival curves were generated and compared using a 2-sided log-rank 
statistic.   
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Metabolic profiling 
Sample Preparation:  Ovarian cancer tissue and normal ovary samples were 
stored at -80oC.  At the time of analysis, samples were extracted and prepared for 
analysis using a standard solvent extraction method.  The sample preparation 
process was carried out using the automated MicroLab STAR® system from 
Hamilton Company.  Recovery standards were added prior to the first step in the 
extraction process for QC purposes.  Sample preparation was conducted using a 
proprietary series of organic and aqueous extractions to remove the protein fraction 
while allowing maximum recovery of small molecules.  The resulting extract was 
divided into two fractions; one for analysis by LC and one for analysis by GC.  
Samples were placed briefly on a TurboVap® (Zymark) to remove the organic 
solvent.  Each sample was then frozen and dried under vacuum.  Samples were 
then prepared for the appropriate instrument, either LC/MS or GC/MS. 
Liquid chromatography/Mass Spectrometry (LC/MS):  The LC/MS portion of 
the platform was based on a Waters ACQUITY UPLC and a Thermo-Finnigan LTQ 
mass spectrometer, which consisted of an electrospray ionization (ESI) source and 
linear ion-trap (LIT) mass analyzer.  The sample extract was split into two aliquots, 
dried, then reconstituted in acidic or basic LC-compatible solvents, each of which 
contained 11 or more injection standards at fixed concentrations.  One aliquot was 
analyzed using acidic positive ion optimized conditions and the other using basic 
negative ion optimized conditions in two independent injections using separate 
dedicated columns.  Extracts reconstituted in acidic conditions were gradient eluted 
using water and methanol both containing 0.1% Formic acid, while the basic 
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extracts, which also used water/methanol, contained 6.5mM Ammonium 
Bicarbonate.  The MS analysis alternated between MS and data-dependent MS 
scans using dynamic exclusion. 
  Gas chromatography/Mass Spectrometry (GC/MS):  The samples 
destined for GC/MS analysis were re-dried under vacuum desiccation for a 
minimum of 24 hours prior to being derivatized under dried nitrogen using 
bistrimethyl-silyl-triflouroacetamide (BSTFA).  The GC column was 5% phenyl 
and the temperature ramp is from 40° to 300° C in a 16 minute period.  
Samples were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning 
single-quadrupole mass spectrometer using electron impact ionization.  The 
instrument was tuned and calibrated for mass resolution and mass accuracy 
on a daily basis.  The information output from the raw data files was 
automatically extracted as discussed below. 
Accurate Mass Determination and MS/MS fragmentation (LC/MS), 
(LC/MS/MS):  The LC/MS portion of the platform was based on a Waters ACQUITY 
UPLC and a Thermo-Finnigan LTQ-FT mass spectrometer, which had a linear ion-
trap (LIT) front end and a Fourier transform ion cyclotron resonance (FT-ICR) mass 
spectrometer backend.    For ions with counts greater than 2 million, an accurate 
mass measurement could be performed.  Accurate mass measurements could be 
made on the parent ion as well as fragments.  The typical mass error was less than 
5 ppm.  Ions with less than two million counts require a greater amount of effort to 
characterize.  Fragmentation spectra (MS/MS) were typically generated in data 
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dependent manner, but if necessary, targeted MS/MS could be employed, such as 
in the case of lower level signals. 
Bioinformatics:  The informatics system consisted of four major components, 
the Laboratory Information Management System (LIMS), the data extraction and 
peak-identification software, data processing tools for QC and compound 
identification, and a collection of information interpretation and visualization tools for 
use by data analysts.  The hardware and software foundations for these informatics 
components were the LAN backbone, and a database server running Oracle 
10.2.0.1 Enterprise Edition. 
Compound identification:  Compounds were identified by comparison to 
library entries of purified standards or recurrent unknown entities.  Identification of 
known chemical entities was based on comparison to metabolomics library entries 
of purified standards.  As of this writing, more than 1000 commercially available 
purified standard compounds had been acquired registered into LIMS for 
distribution to both the LC and GC platforms for determination of their analytical 
characteristics.  The combination of chromatographic properties and mass spectra 
gave an indication of a match to the specific compound or an isobaric entity.  
Additional entities could be identified by virtue of their recurrent nature (both 
chromatographic and mass spectral).  These compounds have the potential to be 
identified by future acquisition of a matching purified standard or by classical 
structural analysis.   
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Normalization:  For studies spanning multiple days, a data normalization step 
was performed to correct variation resulting from instrument inter-day tuning 
differences.  Essentially, each compound was corrected in run-day blocks by 
registering the medians to equal one (1.00) and normalizing each data point 
proportionately.   For studies that did not require more than one day of analysis, no 
normalization is necessary, other than for purposes of data visualization. 
Metabolite statistics:  All Wilcoxon rank-sum tests and t-tests are two-sided 
using a threshold of P < 0.05 for significance. Class-specific metabolomics patterns 
were visualized using heat maps. Unsupervised clustering of samples using 
metabolomics signatures was performed using Cluster and TreeView, and 
visualized using heat maps.  
NAT8L gene expression:   
To determine NAT8L gene expression across different cancer types, RNA 
expression of 20 cancer types were analyzed by RNASeqV2 data available from the 
open access TCGA web page as of Jan 18, 2013 were accessed. The normalized 
counts were log2 transformed (after adding 1) to emphasize differences on a 
multiplicative scale.  The copy number data was analyzed as well using all of the 
public level 3 data available as of Oct 30, 2012.    
To determine gene expression of NAT8L’s association with clinical 
outcomes, RNA expression data was analyzed by RNASeqV2 data available from 
the open access TCGA web site www.cbioportal.org  as of April 2013 were 
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accessed.  Overall survival was analyzed by best cut-off method on provisional 
databases, and based on all tumors from each query.   
To validate gene expression data from non-TCGA cohorts, clinical 
information CEL (Affymetrix U133Plus2)) arrays files from the publication by Tinker 
et al. [166] were analyzed to validate ovarian cancer NAT8L outcomes.  To 
determine NAT8L gene expression’s association with melanoma outcomes, clinical 
information CEL (Affymetrix U133Plus2)) arrays files from the publication Bogunovic 
et al.[167] was accessed for analysis.  Also, clinical information and expression 
values from melanoma samples profiled with Illumina arrays by Jonsson G et 
al.[168]  were analyzed.  All analyses were performed in R (version 2.14.2) 
(http:///www.r-project.org/).   The RMA gene expression values were analyzed, and 
best cut off method to identify clinical outcomes.   For survival analysis the patients 
were grouped into percentiles according to NAT8L expression.  Gene expression by 
best cut-off was done to optimally split the samples into two groups.  The Log-rank 
test was employed to determine the significance of the association between NAT8L 
expression and overall survival.  The Kaplan-Meyer method was used to generate 
survival curves.   
Immunohistochemistry 
Immunohistochemical (IHC) analysis was done on formalin-fixed, paraffin-
embedded samples, using standard techniques. For NAT8L, antigen retrieval was in 
citrate buffer for 45 minutes in an atmospheric pressure steamer, using anti-NAT8L 
antibody (Sigma-Aldrich) at 1:100 dilution was incubated overnight at 4°C. Primary 
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antibody detection was with Biotenelatled HRP polymer for 6 minutes at room 
temperature, followed by diaminobenzidine incubation. After IHC staining, a semi-
quantitative H-score was done. Briefly, the intensity of tumor cells positive for 
NAT8L was 1= weak, 2 = moderate, or 3= strong intensity.  NAT8L counted and 
expressed as a percentage of all tumor cells by an examiner blinded to clinical 
outcome. Patient samples were categorized as having low (<25%) =1, intermediate 
(25 %< x<75%) =2 or high (>75%) =3.  The product of percentage of cell score and 
intensity score equaled the H-Score.  The IHC analysis was done on samples 
collected at primary debulking surgery on 209 untreated patients with stage III–IV, 
high-grade papillary serous adenocarcinoma; with institutional review board 
approval, clinical information was collected. Progression-free and overall survival 
were plotted with the Kaplan–Meier method for patients in each group of NAT8L 
expression and compared with the log-rank statistic. 
Gene Array 
Gene array data from HeyA8 ovarian cancer cells double transfected with NAT8L 
siRNA and NT siRNA were deposited into the GEO database.  Array data 
processing was performed on Illumina BeadStudio software. We normalized gene 
expression data using Quantile normalization and log2 transformation. To export to 
a data matrix, Sample Gene Profile option of this software was used. BRB-
ArrayTools were primarily used to identify genes differentially expressed between 
the 2 subgroups [169], and all other statistical analyses were performed in the R 
language environment. Gene expression differences were considered significant 
if P values were less than 0.001.  A random-walk based network scoring method, 
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NetWalker, for genomic data analysis was employed (Komurov, White et al 2010). 
 The replicates in gene expression array (siRNA NAT8L in HeyA8) were averaged 
and the ratio of average siRNA NATBL/average Control in HeyA8 was considered. 
The gene names were converted into HUGO formats. Unbiased network of the top 
down and up regulating genes (considered around top 100 interactions) is displayed 
by running NetWalker on the entire gene set. 
Reverse Phase Protein Array 
HeyA8 cell lines were double transfected with NAT8L siRNA and NT siRNA.  
Cellular proteins were denatured by 1% SDS (with beta-mercaptoethanol) and 
diluted in five 2-fold serial dilutions in dilution buffer (lysis buffer containing 1% 
SDS). Serial diluted lysates were arrayed on nitrocellulose-coated slides (Grace 
Biolab) by Aushon 2470 Arrayer (Aushon BioSystems). Total 5808 array spots were 
arranged on each slide including the spots corresponding to positive and negative 
controls prepared from mixed cell lysates or dilution buffer, respectively. 
Each slide was probed with a validated primary antibody plus a biotin-
conjugated secondary antibody. Only antibodies with a Pearson correlation 
coefficient between RPPA and western blotting of greater than 0.8 were used in 
reverse phase protein array study. Antibodies with a single or dominant band on 
western blotting were further assessed by direct comparison to RPPA using cell 
lines with differential protein expression or modulated with ligands/inhibitors or 
siRNA for phospho- or structural proteins, respectively. 
The signal obtained was amplified using a Dako Cytomation–catalyzed 
system (Dako) and visualized by DAB colorimetric reaction. The slides were 
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scanned, analyzed, and quantified using a customerized-software Microvigene 
(VigeneTech Inc.) to generate spot intensity. 
Each dilution curve was fitted with a logistic model (“Supercurve Fitting” 
developed by the Department of Bioinformatics and Computational Biology in MD 
Anderson Cancer Center, “http://bioinformatics.mdanderson.org/OOMPA”). This fits 
a single curve using all the samples (i.e., dilution series) on a slide with the signal 
intensity as the response variable and the dilution steps are independent variable. 
The fitted curve is plotted with the signal intensities – both observed and fitted - on 
the y-axis and the log2-concentration of proteins on the x-axis for diagnostic 
purposes. The protein concentrations of each set of slides were then normalized by 
median polish, which was corrected across samples by the linear expression values 
using the median expression levels of all antibody experiments to calculate a 
loading correction factor for each sample. "Linear after normalization" values were 
transformed to Log2 values and median centered for hierarchical clustering 
analysis.  Heatmaps for unsupervised hierarchical clustering (antibody 
unsupervised but samples in order for reference).  The heatmap was generated in 
Cluster 3.0 (http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm) as a 
hierarchical cluster using Pearson correlation and a centered metric. The resulting 
heat map was visualized in Treeview (http://www.eisenlab.org/eisen).   
Network of the top up and down regulating proteins and phosphorylated 
proteins was displayed. The protein names were converted into HUGO formats. 
NetWalker was used to display the network of the proteins in red-green colormap 
and the phosphor-proteins in the yellow-blue colormap.  Note that if for some 
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protein the total and phosphor both were down (or up, respectively) then the color is 
dominated by the level of the total protein.  The RPPA data was median centered 
and the ratio of the NAT8L/Control was considered to draw these networks.  
Cell lines and culture conditions 
      The derivation of the human ovarian cancer cell lines A2780, HeyA8, SKOV3-
IP1, are previously reported [170,171,172,173,174]. The cell lines A2780, HeyA8, 
and SKOV3-IP1 were maintained in RPMI-1640 medium with 15% Fetal Bovine 
Serum (FBS). HeyA8-MDR and SKOV3-TR are taxane-resistant derivations of 
HeyA8 and SKOV3ip1 (Dr. Isaiah J. Fidler, MDACC, Houston, TX).  The taxane-
resistant phenotype was maintained by adding 300 ng/mL (HeyA8-MDR) and 100 
ng/mL (SKOV3-TR) of paclitaxel to the media used for HeyA8 and SKOV3-ip1.  The 
human melanoma cell line A375SM was established from pooled lung metastases 
produced by A375-P cells injected intravenously into nude mice [175]. These cells 
were maintained in Eagle's minimal essential medium supplemented with 10% fetal 
bovine serum (FBS)[176]. The melanoma cell lines UACC 62, UACC 257, and M14 
were obtained from Dr. Suhendan Ekmekcioglu (The University of Texas-MD 
Anderson Cancer Center; Houston, Texas), and were maintained in MEM 
supplemented with 10% fetal bovine serum, 100 μg/ml glutamine, penicillin (100 
units/mL), and streptomycin (100 μg/mL) (Invitrogen, Carlsbad, CA).  The Ishikawa 
human endometrial cancer cell line was maintained in MEM supplemented with 
10% FBS and 0.1% gentamicin sulfate (gift from Dr. Russell Broaddus, MDACC, 
Houston, TX) [177].  Cell lines were also routinely tested to confirm absence of 
Mycoplasma.  Cells were maintained at 37°C in a humidified incubator infused with 
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20% O2 and 5% CO2.   
Orthotopic model of ovarian cancer and melanoma in nude mice 
Female athymic nude (NCr-nu) were purchased from Taconic Farms, Inc. 
(Rockville, MD). The development and characterization of the orthotopic mouse 
model of ovarian cancer has been previously described [178,179,180]. Briefly, 
SKOV3-IP1 (1 x 106), A2780 (1 x 106), HeyA8 (0.25 x 106) human ovarian cancer 
cells were lifted with trypsin/edta, washed with PBS, and resuspended in 200 µL of 
Hank’s balanced salt solution (HBSS, Mediatech, Inc. Manassas, VA) and were 
injected into the peritoneal cavity of female nude mice.  A375-SM subcutaneous 
tumors were produced by injecting 1 × 106 cells/0.2 ml HBSS over the right hip 
region of the mice. Growth of subcutaneous tumors was monitored by weekly 
examination of the mice and measurement of tumors with calipers.  All cell lines 
have been shown to reliably form macroscopic tumor implants on peritoneal 
surfaces throughout the pelvis and abdominal cavity.   
Tumor weight was recorded at the time of necropsy and tumor tissue was 
harvested for histopatholoigcal analysis.  Proliferation index and apoptosis were 
evaluated in tumor sections with immunohistochemical staining for Ki67 and 
cleaved caspase-3 antigens, respectively.  Frozen sections were fixed in acetone + 
chloroform 1:1 for 5 minutes between two 5 minute incubations in cold acetone 
alone.  Endogenous peroxidases and non-specific epitopes were blocked with 3% 
H2O2 in PBS and 5% normal horse serum + 1% normal goat serum in PBS, 
respectively.  Sections were then incubated with primary antibody directed against 
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either Ki-67 (1:200, Neomarker, Fremont, CA) or CD31 (1:800, Cell Signaling, 
Danvers, MA) at 4°C overnight.  After washing with PBS, the appropriate HRP-
conjugated secondary antibody in blocking solution was added for 1 hour at room 
temperature.  Slides were developed with 3, 3’-diaminobenzidine (DAB) chromogen 
(Invitrogen, Carlsbad, CA) and counterstained with Gil No.3 hematoxylin (Sigma-
Aldrich, St. Louis, MO).  Proliferative index and cleaved caspase 3 index was 
calculated by dividing the number of positive nuclei (brown) or by the total number 
of cells for each of 5 randomly selected 200x high power fields per tumor specimen 
for each treatment group. 
Forward transfection 
 In the case of forward transfection, 6-well plates were inoculated with 
150,000 cancer cells per well with a goal of transfection at 50% confluence within 
12-24 hours of plating. Based on validation experiments, the appropriate amount of 
the siRNA of choice was incubated for 20 minutes at room temperature in serum-
free culture medium (1 mL/well) with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) 
at a 3:1 ratio of volume (µL) Lipofectamine 2000 to microgram siRNA. After 
incubation, siRNA/Lipofectamine-containing medium were added to cells and media 
to achieve a siRNA concentration of 50 nM. Cells and transfection media were 
incubated at 37oC for 4 hours, and then transfection medium was changed to 
serum-containing medium.  
Reverse transfection 
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 In the case of reverse transfection, and based on previously performed 
validation experiments, the appropriate amount of the siRNA of choice was 
incubated for 20 minutes at room temperature in serum-free culture medium (500 
mcL/well) with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) at a 5:1 ratio of 
volume of Lipofectamine RNAiMAX to mcL siRNA. After incubation, 500 mcL of the 
solution was placed in each well, and then 75,000 cancer cells in 2.5 mL of serum-
free media were added to each well to achieve a final siRNA concentration of 50 
nM. Cells were incubated with the transfection medium for 4-6 hours at 37oC, and 
then medium was changed to serum-containing medium.  
Double transfection 
 If a longer duration of mRNA knockdown was needed than was offered by 
single forward or reverse transfection, then sequential double transfection was 
used. In this case, forward transfection was initially performed, and 72 hours later, a 
reverse transfection was performed. 
RNA Extraction 
      Total RNA was extracted from cells growing in vitro using RNeasy Kit (Quiagen, 
Venlo, Netherlands). Cells were lifted with trypsin/edta, washed with PBS, and 
centrifuged at 10,000 rpm for 5 minutes to form the pellet. The supernatant was 
discarded, and RNA was extracted according to the company protocol. RNA was 
quantified using a spectrophotometer and 1 µg was transcribed into complementary 
DNA (cDNA) using the Verso cDNA kit (Thermo Fisher Scientific), closely following 
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the manufacturer’s protocol.  Quantitative RT PCR was then used to assess levels 
of expression.                           
In vitro apoptosis 
 Cells were plated in 6-well plates at 150,000 cells per plate, targeting 
approximately 50% confluence in serum-containing medium.   After two rounds of 
transfection with siRNA (144 hours), cell viability was assessed using Annexin V 
and 7-amino-actinomycin-D (7AAD) staining (BD PharmingenTM, Franklin Lakes, 
NJ) by flow cytometry. Briefly, cells were harvested, washed in PBS, and incubated 
with PE-Annexin V and 7AAD according to package insert instructions for 20 
minutes prior to flow cytometric analysis. 
In vitro proliferation 
Cells were plated in 6-well plates at 150,000 cells per plate, targeting 
approximately 50% confluence in serum-containing medium. After two rounds of 
siRNA transfection at time point 96 hours, the percentages of cells proliferating 
(defined as S-phase) were determined using the Click-iT EdU flow cytometry kit 
(Invitrogen, Carlsbad, CA). Cells were incubated with 10 mcM 5-ethynyl-2-
deoxyuridine (EdU) for 2 hours, lifted, and washed with 1% bovine serum antigen in 
d-PBS. Cells were fixed with 4% paraformaldehyde in d-PBS for 15 minutes at room 
temperature and then maintained at 4oC protected from light until the time of flow 
cytometric analysis, duration not to exceed 7 days. On the day of analysis, cells 
were washed in 1% BSA in d-PBS and then permeabilized with 1x saponin-based 
reagent for 15 minutes at room temperature. The cells were then incubated with a 
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solution of 1x reaction buffer, CuSO4, Alexa-Fluor 488 azide dye, and proprietary 
reaction buffer additive for 30 minutes at room temperature prior to flow cytometric 
analysis. 
In vitro cell cycle 
For cell-cycle analysis, cells were transfected with siRNA as described for 48 
hours, trypsinized, washed in PBS, and fixed in 75% ethanol overnight. Cells were 
then centrifuged, washed twice in PBS, and reconstituted in PBS with 50 μg/mL of 
propidium iodide. Propidium iodide fluorescence was assessed by flow cytometry. 
In vitro invasion and migration 
 A polycarbonate membrane with 10-μm pores (Osmonics, Livermore, CA) 
was uniformly coated with a defined basement membrane matrix consisting of 
human laminin/type IV collagen/gelatin and used as the intervening barrier to 
invasion.   The bottom well contained 500 µl of 5% FBS media.  Cancer cells were 
added to the top wells with approximately 100,000 cells/well in serum free media. 
After 24-hour incubation in a humidified incubator at 37°C with 5% CO2, cells that 
had invaded through the basement membrane were collected, stained, and counted 
by light microscopy[181]. Motility (migration) was determined in membrane invasion 
culture system chambers containing polycarbonate filter (with 10 μm pores) that had 
been soaked in 0.1% gelatin. Tumor cells (5 × 104) were seeded in each upper well, 
allowed to incubate at 37°C for 6 hours in complete media, and subsequently 
processed as described for the invasion assay. 
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Results 
Metabolic Profile of high grade serous epithelial ovarian cancer  
To evaluate the global metabolic profile of human epithelial ovarian cancer 
(n=71) tissues and normal non-cancerous ovarian tissue (n=15), we used both 
liquid and gas chromatography coupled with mass spectrometry to identify relative 
metabolite levels.  A total of 313 metabolites were identified between these two 
groups (Figure 2), of which 172 were significantly altered (p<0.05) between ovarian 
cancer tissues and normal ovary tissues. Of those 172 significantly altered 
metabolites, 142 were elevated and 30 were decreased in ovarian cancer.  For 
visualizing the relationship between the 172 altered metabolites, hierarchical 
clustering was used to arrange the metabolites on the basis of their relative 
abundance levels across samples (Figure 3). 
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Figure 2.  Global metabolic profile of ovarian cancer and normal ovary.  
Hierarchical clustering of 313 metabolites identified in LC/MS and GC/ MS 
metabolic progiling of ovarian cancer (n=72) and normal ovarian sample (n=15).  
Analysis reported with relative intensity to the median value for each metabolite set 
to 1. 
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Figure 3.  Significantly altered metabolites in ovarian cancer.  
Hierarchical clustering of 172 significantly altered metabolites (p<0.05).   
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Of the 142 metabolites that were significantly up-regulated, the majority involved 
the lipid pathway (53.5%); this was followed by amino acid (19.0%), carbohydrate 
(9.9%), and nucleotide metabolic pathways (9.2%) (Figure 4).   
 
 
 
Figure 4.  Pathways affected by altered metabolism in ovarian cancer.  
 
Although lactate levels were not significantly elevated in ovarian cancer as 
compared to the normal ovary, the changes observed in the glycolytic intermediates 
was consistent with increased glucose metabolism in ovarian cancer.  Increased 
levels of 6-carbon glycolytic intermediates glucose-6-phosphate (G6P) and fructose-
6-phosphate (F6P) reflect increased utilization of intracellular glucose, while 
decreased levels of glucose, 3-phosphoglycerate (3-PG), 2-phosphoglycerate (2-
PG) and phosphoenolpyruvate (PEP) suggest increased glycolytic activity with 
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contributions to lipid, amino acid, and nucleotide synthesis through pentose 
phosphate pathway (Figure 5). 
 
Figure 5. Increased glucose metabolism in ovarian cancer.  Values are mean 
values of the relative intensity ± SEM.   
 
Indeed, ovarian cancer revealed low 6-phosphogluconate, and elevated 
ribose-5-phosphate, and sedoheptulose-7-phosphate further suggesting increased 
activity of the pentose phosphate pathway (PPP) to promote NADPH production 
and nucleotide synthesis (Figure 6). 
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Figure 6.  Increased PPP metabolism in ovarian cancer.  Values are mean 
values of the relative intensity ± SEM.   
 
The major pathway altered in ovarian cancer from the normal ovary was the 
lipid pathway.   Ovarian cancer showed significantly elevated levels for essentially 
all long-chain fatty acids, with the notable exception of arachidonate and adrenate 
(Table 2).  
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Table 2.  Elevation of long-chain fatty acids in ovarian cancer.  Fold changes 
are the mean relative values of ovarian cancer over the normal ovary.  NS is 
p>0.05. 
Metabolite Fold Change p-value 
conjugated linoleate 4.19 1.86E-05 
eicosenoate (20:1n9 or 11) 3.50 1.32E-06 
10-nonadecenoate (19:1n9) 3.06 5.70E-06 
behenate (22:0) 2.81 6.10E-05 
docosadienoate (22:2n6) 2.61 0.0002 
dihomo-linoleate (20:2n6) 2.33 0.0005 
palmitoleate (16:1n7) 2.24 2.33E-05 
10-heptadecenoate (17:1n7) 2.18 4.39E-05 
docosatrienoate (22:3n3) 2.10 0.0148 
oleate (18:1n9) 1.89 0.0004 
myristoleate (14:1n5) 1.73 0.0002 
nonadecanoate (19:0) 1.72 2.07E-10 
stearidonate (18:4n3) 1.67 NS 
margarate (17:0) 1.66 1.80E-06 
adrenate (22:4n6) 1.46 NS 
pentadecanoate (15:0) 1.44 0.0306 
myristate (14:0) 1.39 0.0053 
palmitate (16:0) 1.38 0.0027 
arachidonate (20:4n6) 1.24 NS 
stearate (18:0) 1.20 0.0073 
 
The most up-regulated long chain fatty acid was the bacterial gut derived 
conjugated linoleate (Fold change 4.19, p-value 1.86E-05).  Also, odd-numbered 
carbon chain fatty acids such as pentadecanoate and margarate, and both 
saturated (e.g. palmitate and stearate) and unsaturated (e.g. palmitoleate and 
oleate) fatty acids were elevated.  Interestingly, in ovarian cancer, there are 
significantly increased levels of the essential fatty acids linoleic acid (n-6), and 
linolenic acid (n-3) (Figure 7).  Importantly, n-6 and n-3 levels are the precursors for 
prostaglandins, thromboxanes, leukotrienes, hydroxy fatty acids, and lipoxins[182].  
Higher levels of these compounds are associated with a pro-inflammatory state in 
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cancer.  Indeed, a significant up-regulation of eicosanoids were seen in the ovarian 
cancer samples compared to the normal ovarian tissue with prostaglandin E2 being 
the highest up-regulated eicosanoid (Fold change 15.15, p-value: 4.09E-08) (Table 
3).   
 
 
Figure 7. Elevated levels of the essential fatty acids, linoleic acid (n-6) and 
linolenic acid (n-3), in ovarian cancer . Values are relative scaled intensity mean 
values±SEM.  
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Table 3.  Up-regulation of eicosanoids in ovarian cancer.  Fold changes are the 
mean relative values of ovarian cancer over the normal ovary.  NS is p>0.05. 
 
Metabolite Fold Change p-value 
prostaglandin E2 15.15 4.09E-08 
6-keto prostaglandin F1alpha 11.12 1.88E-06 
prostaglandin I2 8.25 8.21E-06 
prostaglandin A2 6.80 5.14E-05 
15-HETE 6.28 8.81E-05 
prostaglandin D2 5.87 1.00E-04 
prostaglandin E1 5.04 1.05E-06 
thromboxane B2 2.57 1.72E-06 
 
Along with the up-regulated fatty acids and eicosanoids in the lipid pathway, a 
similar lipid profile was seen with multiple components of the phospholipid 
biosynthetic pathways to support elevated membrane demands of cancer.  There 
were significantly elevated levels of the membrane phospholipid precursor 
compounds such as choline, ethanolamine, and cytidine 5'-diphosphocholine  
(CDP-choline), and multiple lysophospholipid intermediates in membrane 
phospholipid biosynthesis (e.g. 2-myristoylglycerophosphocholine, 2-
palmitoleoylglycerophosphoethanolamine, and 1-stearoylglycerophosphoinositol).  
These changes along with changes in cholesterol metabolism together indicate the 
massively altered membrane phospholipid metabolism in cancer.  
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Brain specific N-acetylaspartate (NAA) is one of the highest up-regulated 
metabolites in ovarian cancer 
For further evaluation of each individual of the 142 metabolites that were 
significantly up-regulated, we narrowed our list to the 20 highest fold changes of 
metabolites in ovarian cancer (Table 4).  
Table 4.  Twenty highest up-regulated metabolites in ovarian cancer.  Fold 
changes are the mean relative values of ovarian cancer over the normal ovary.   
 
Metabolic 
Pathway 
Metabolite 
Fold 
Change 
p-value 
Nucloetide adenosine 5'-monophosphate (AMP) 58.54 2.53E-06 
Lipids CDP-choline 30.38 1.00E-16 
Amino Acid N-acetylaspartate (NAA) 28.38 2.30E-11 
Lipids 2-oleoylglycerophosphocholine 19.4 1.13E-10 
Lipids prostaglandin E2 15.15 4.09E-08 
Amino Acid 5-methylthioadenosine (MTA) 13.13 3.94E-12 
Lipids 6-keto prostaglandin F1alpha 11.12 1.88E-06 
Amino Acid gamma-aminobutyrate (GABA) 11.07 0.001 
Lipids 1-palmitoylglycerophosphocholine 10.19 6.06E-06 
Carbohydrates UDP-glucuronate 9.27 3.10E-09 
Amino Acid N-acetyl-aspartyl-glutamate (NAAG) 9.14 3.51E-10 
Lipids 1-oleoylglycerophosphocholine 9.07 1.39E-07 
Lipids 2-palmitoylglycerophosphocholine 8.38 2.91E-07 
Lipids prostaglandin I2 8.25 8.21E-06 
Nucloetide thymine 7.83 8.27E-07 
Lipids 2-arachidonoylglycerophosphocholine 7.72 8.93E-05 
Lipids prostaglandin A2 6.8 5.14E-05 
Lipids 1,2-propanediol 6.77 0.0105 
Amino Acid 4-hydroxyphenylpyruvate 6.63 9.23E-08 
Lipids 15-HETE 6.28 8.81E-05 
 
Again, the majority of the highest up-regulated metabolites involved lipid and 
amino acid pathways.  The highest fold change was the nucleotide and energy 
signaling molecule adenosine 5'-monophosphate (AMP), followed by the lipid 
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membrane precursor CDP-choline, and NAA.  Since these fold changes were based 
on mean values, and there are skewed distributions across metabolites,  we 
analyzed the median values of the top 8 up-regulated metabolites from table 1 to 
further determine which metabolites are consistently more abundant in ovarian 
cancer.  Of these 8, NAA had the highest median level in ovarian cancer (Figure 8). 
 
 
 
 
 
Figure 8.  Median levels of the highest fold-change metabolites in ovarian 
cancer and in the normal ovary.  
 
NAA was one of the most significant alterations in ovarian cancer tissues 
compared to the normal ovary. NAA was greater than 28 fold up-regulated in 
ovarian cancer compared to the normal ovary (2.30E-11) (Table 4).  NAA levels in 
ovarian cancer tumors were strongly positively correlated with the brain dipeptide N-
 54 
 
acetyl-aspartyl-glutamate (NAAG) (r=0.85, p<0.001), along with several eicosanoids 
including prostaglandins E1 (r=0.54, p<0.001) and E2 (r=0.50, p<0.001), the TCA 
cycle substrate malate (r=0.45, p<0.001), and AMP (r=0.40, p<0.001) (Table 5).  
NAAG was greater than 9 fold elevated in ovarian cancer (p<3.51E-10) (Table 4).   
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Table 5.  Metabolites associated with NAA levels.  List of metabolites that were 
strongly significantly associated with NAA levels.  
 
 
As mentioned, there are several known biochemical reactions that form and 
breakdown NAA (Figure 9).  The main biosynthetic enzyme for NAA is Aspartate N-
acetyltransferase (NAT8L).  The substrates for the NAT8L enzyme are acetyl-coA 
and aspartic acid which form NAA and coA.  This hydrolysis of NAAG releases 
glutamate and NAA.   The main breakdown enzyme for NAA is aspartocyclase 
(ASPA).  NAA is hydrolyzed by ASPA into aspartate and a carboxylate, typically 
acetate.  NAA reacts with glutamate to form NAAG by the enzyme NAAG 
Synthetase encoded by RIMKLB. To determine if the elevation in NAA was 
associated with its accumulation or its breakdown, we determined patient gene 
Metabolite Super-Pathway 
Spearmon’s 
r p-value 
N-acetyl-aspartyl-glutamate  
(NAAG) Amino acid 0.85 <0.001 
prostaglandin E1 Lipid 0.54 <0.001 
6-keto prostaglandin F1-alpha Lipid 0.52 <0.001 
homocysteine Amino acid 0.51 <0.001 
prostaglandin E2 Lipid 0.50 <0.001 
prostaglandin I2 Lipid 0.46 <0.001 
malate Energy 0.45 <0.001 
thromboxane B2 Lipid 0.44 <0.001 
nicotinamide Cofactors and vitamins 0.44 <0.001 
gamma-glutamylalanine Peptide 0.44 <0.001 
prostaglandin D2 Lipid 0.42 <0.001 
inositol 1-phosphate (I1P) Lipid 0.42 <0.001 
phenyllactate (PLA) Amino acid 0.41 <0.001 
3-(4-hydroxyphenyl)lactate Amino acid 0.41 <0.001 
adenosine 5'-monophosphate 
(AMP) Nucleotide 0.40 <0.001 
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expression levels of NAT8L, FOLH1, and NAALAD2 as the NAA accumulation 
genes. ASPA and RIMKLB gene expression levels were evaluated as the NAA 
breakdown genes (Figure 10). NAA levels was strongly correlated with NAT8L gene 
expression levels (r=0.52, p<0.0001), FOLH1 was weakly correlative (r=0.25, 
p=0.017), and NAALAD2 was weakly negatively correlative (r= -0.24, p=0.023).  
ASPA and RIMKLB had no correlation with NAA levels.  This suggests that high 
NAA levels in ovarian cancer are driven by up-regulation of its biosynthesis NAT8L.  
Furthermore, the low levels of its substrate aspartate in ovarian cancer further 
suggest that NAA biosynthesis as the cause of high NAA levels (Figure 11).   
One possibility of elevated NAA is due to global up-regulation of N-acetylation 
across various amino acids.  However, our metabolic profile did not show a 
consistent pattern of elevated N-acetyl amino acids (Table 6).  In fact, aspartic acid 
was disproportionately more N-acetylated than all of the N-acetylated amino acids 
in ovarian cancer.  This suggests that elevated NAA is not a result of global N-
acetylation processes of amino acids; rather, there is a significant selection for N-
acetylation of aspartic to form NAA in ovarian cancer. 
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Table 6.  Fold change N-acetylation of amino acids in ovarian cancer.  Fold 
change is relative intensity of ovarian cancer over the normal ovary.  
[red box= up regulation(p<0.05), green box= down regulation (p<0.05)] 
Amino Acid Fold Change N-acetylated amino acid Fold change 
serine 1.03 N-acetylserine 0.88 
threonine 1.1 N-acetylthreonine 1.6 
alanine 1.35 N-acetylalanine 0.91 
aspartate 0.71 N-acetylaspartate (NAA) 28.38 
glutamate 1.14 N-acetylglutamate 4.62 
tryptophan 0.87 N-acetyltryptophan 0.65 
methionine 0.97 N-acetylmethionine 0.76 
ornithine 0.48 N-acetylornithine 0.8 
putrescine 3.72 N-acetylputrescine 2 
glycine 1.27 N-acetylglycine 0.7 
 
To validate that NAA levels were significantly higher in ovarian cancer 
compared to the normal ovary, we evaluated a separate cohort of ovarian cancer 
(n=47) and normal ovarian samples (n=3) using NMR spectroscopy.  NMR also has 
the advantage of giving exact quantification of metabolite concentrations.  Indeed, 
the NAA peak at 2.0-2.1 ppm was distinctly seen in ovarian cancer samples, and 
absent in the normal ovary (Figure 12a).  Ovarian cancer samples had significantly 
higher levels of NAA compared to the normal ovary (Figure 12b) with concentrations 
on average at 104.2 µM (±14.57 SEM), and NMR could not detect any NAA in 
normal ovaries (p<0.0001).   
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Figure 9. Schema of the NAA-NAAG pathway.  NAA is biosynthesized by 
aspartate N-acetyltransferase (NAT8L) from acetyl CoA (Ac-CoA) and aspartate.  
NAA is metabolized into acetate and aspartate by aspartoacyclase (ASPA).  NAA 
can also form NAAG by reacting with glutamate by the enzyme NAAGS encoded by 
RIMKLB gene.  NAAG can also revert back to NAA and glutamate by the enzymes 
GCP-II encoded by FOLH1 or by GCP-III encoded by NAALAD2.  
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Figure 10. NAT8L is strongly correlated with NAA levels in ovarian cancer.  
Spearmon’s correlation (r )  of relative NAA levels in 101 ovarian cancer patients 
and patient gene expression levels of the NAA pathway.   
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Figure 11. Low levels of aspartic acid in ovarian cancer.  Aspartate levels of 101 
ovarian cancer samples and 15 normal ovary samples shows lower levels of 
aspartate in ovarian cancer compared to the normal ovary.  
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Figure 12.  NMR spectroscopy:  higher levels of NAA in ovarian cancer.   a.) 
NMR spectra of 3 ovarian cancer samples and 2 normal ovary samples shows the 
distinct NAA peak in ovarian cancer. (blue, purple, red color spectra=  3 ovarian 
cancer samples; black and green color spectra= 2 normal ovary samples) b.) NMR 
spectroscopy of NAA samples showing the levels of NAA in 69 ovarian cancer 
samples and 10 normal ovaries.  
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Clinical implications of NAA biosynthesis 
On the basis of substantial elevations in NAA observed in ovarian cancer, we 
next wondered if there were any clinical implications of these elevations.  We 
investigated the relative NAA levels of 101 ovarian cancer samples using GC/LC 
mass spectrometry.  Patients with higher levels of NAA had worsening overall 
survival compared to patients with low NAA levels (Figure 13).  High NAA overall 
survival was 1295 days and low NAA survival was not reached (p=0.038). 
 
 
Figure 13.  High NAA levels are associated with worsening overall 
survival in ovarian cancer.  Kaplan-Meier analysis of relative NAA levels and 
overall survival in 101 ovarian cancer patients.   
 
On the basis of NAA levels being strongly correlated with NAT8L gene 
expression, we next examined clinical outcomes of 485 patients based on NAT8L 
gene expression from the TCGA.  Analysis of RNASeq gene expression data 
revealed that high expression of NAT8L (cut-off > 0.5 z-score) is associated with 
 63 
 
worse overall survival in high grade serous ovarian cancer (Figure 14a).  The 
median overall survival of the high NAT8L expression was 35 months compared to 
45 months in the low NAT8L group (p=0.031).  To validate, we analyzed a second 
independent cohort of 285 ovarian cancer patients (Figure 14b). Concordantly, high 
NAT8L (cut-off > 47th percentile) gene expression was associated with worse 
overall survival compared to the low NAT8L gene expression group.  The median 
overall survival of the high NAT8L expression were  40 months compared to 52 
months in the low NAT8L group (p=0.005). Finally, we evaluated mRNA levels of 
NAT8L in a cohort of ovarian cancer patients from our institution (n= 135) and 
normal non-cancerous ovaries (n=15).  Ovarian cancer patients had over a 3 fold 
increased levels of NAT8L expression compared to the normal ovary (p<0.001) 
(Figure 15). 
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Figure 14.  High NAT8L gene expression is associated with worse overall 
survival.  a.) Kaplan Meier analysis of NAT8L gene expression and overall survival 
using RNASeq platform in TCGA. b.) Kaplan Meier analysis of NAT8L gene 
expression and overall survival from Tothill gene expression database. 
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Figure 15.  NAT8L gene expression is significantly higher in ovarian cancer.  
RT-PCR of NAT8L gene expression comparing ovarian cancer samples (n=135) to 
normal ovary samples (n=15).  Mean RQ values ± SEM.   
 
To determine if NAT8L protein levels were also significantly elevated in 
ovarian cancer and the normal ovary, we examined 209 ovarian cancer patients and 
10 normal ovary tissues from our institution using immunohistochemistry of anti-
NAT8L protein in a tissue microarray.  We found significantly higher expression of 
NAT8L compared to the normal ovary (Figure 16).  Based on a semi-quantitative H-
score method, ovarian cancer had a 1.92 fold higher levels of NAT8L staining 
compared to the normal ovary (p<0.0001). Furthermore, higher NAT8L staining was 
associated with poor overall survival in ovarian cancer (Figure 17).  High NAT8L 
expression was associated with 3.86 years overall survival compared to 9.09 years 
with low NAT8L expression (p<0.001). 
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Figure 16.   Ovarian cancer has significantly higher NAT8L protein levels 
compared to the normal . Immunohistochemistry of anti-NAT8L in 208 ovarian 
cancer samples and 10 normal ovarian samples.  *=p<0.001.   
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Figure 17.  High NAT8L protein levels are associated with worse overall 
survival in ovarian cancer.  Kaplan-Meier analysis of NAT8L protein expression 
and overall survival in 208 ovarian cancer samples.   
 
On the basis that high NAT8L up-regulation is driving NAA accumulation in 
ovarian cancer; we considered the relative NAT8L gene expression across various 
cancer types in the TCGA.  We evaluated the relative gene expression levels and 
copy number alterations of NAT8L from across the 20 cancer types.  Surprisingly, 
we found relatively high levels of NAT8L expression in HSOEC, skin cutaneous 
melanoma; glioblastoma multiforme (GBM), kidney chromophobe, and brain lower 
grade glioma cancer having the  highest expressions of NAT8L in the TCGA (Figure 
18) (Table.   Breast, uterine endometroid, and thyroid cancer also had relatively 
high NAT8L expression among the 20 tumors assessed from the TCGA.  NAT8L 
 68 
 
copy number alterations distinctly showed that ovarian cancer had the greatest 
degree of copy number alterations among the 20 cancer types (Figure 19). 
 
Figure 18.  NAT8L gene expression across 20 different tumor types. Gene 
expression data of NAT8L Log2 normalized from TCGA. 
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Table 7.  TCGA acronymns for figure 18 and 19.    
Acronymn Tumor Type 
BRCA Breast cancer 
KIRC Renal clear cell 
COAD, READ Colon and Rectal adenocarcinoma 
UCEC Endometrial Cancer 
GBM Glioblastoma multiforme 
LUSC Lung squamous carcinoma 
OV Ovarian 
LUAD Lung adenocarcinoma 
HNSC Head and neck squamous cell 
carcinoma 
THCA Pappillary thyroid cancer 
SKCM Cutaneous melanoma 
STAD Stomach adenocarcinoma 
BLCA Bladder cancer 
LGG Lower grade glioma 
CESC Cervical 
LAML Acute Myeloid leukemia 
DLBC Diffuse large B cell lymphoma 
ESCA Esophageal carcinoma 
KIRP Papillary kidney 
LIHC Liver 
PAAD Pancreatic adenomcarcinoma 
PRAD  Prostate adenocarcinoma 
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Figure 19.  NAT8L copy number alterations across 20 types. TCGA Copy 
number alterations Log2 transforemed. 
 
Based on the fact that NAT8L gene expression levels were comparatively 
high across several tumor types, we evaluated the TCGA database to determine if 
high NAT8L affects clinical outcomes in other cancer types.  Using the publically 
available website www.cbioportal.org, TCGA survival data for NAT8L was analyzed.  
TCGA currently does not have melanoma survival data, therefore we analyzed two 
different patient cohort gene arrays in melanoma.  Profoundly, high NAT8L 
expression was found to have worse overall survival in invasive breast, lung 
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squamous, colon, uterine, melanoma and kidney renal cell cancers (Figure 20).  
Thus suggesting that worsening survival due to elevated NAA biosynthesis is not 
unique only to ovarian cancer. 
 
Figure 20.  High NAT8L with worse overall survival in several cancer types.  
NAT8L gene expression data from TCGA (breast cancer, lung squamous, colon 
adenocarcinoma, uterine endometrioid carcinoma, renal cell carcinoma) and 
melanoma gene expression from previously published database [167-168]. 
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Biologic significance of NAA synthesis 
To determine the biological significance of NAA biosynthesis in ovarian cancer, 
we next screened the CCLE and NCI-60 database to identify cell lines and cancer 
types with high NAT8L expression.  Indeed in the CCLE, ovarian cancer cell lines 
had some of the highest expressions of NAT8L (Figure 21).  We also analyzed the 
NCI-60 cell lines, the median (±S.D.) NAT8L expression level of all 60 cancer lines 
was 4.45(±0.81) GCRMA.  Melanoma, lung, renal, and ovarian cancer cell lines had 
some of the highest expression of NAT8L (Figure 22). 
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Figure 21.  Gene expression of NAT8L from CCLE.   Gene expression of cell 
lines clustered by cancer type.  Numbers in paraenthesis after each cancer type are 
the number of cell lines.   
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Figure 22. NCI-60 cell lines with high NAT8L gene expression (sorted by top 
50%). LC=lung cancer, ME=melanoma, RE= renal, OV= ovary, CO=colon cancer, 
PR=prostate cancer, BR=breast, LE=leukemia. 
 
 
 
To determine the effects of NAT8L inhibition in cancer cells, siRNA was used to 
reduce NAT8L levels in cancer cell lines.  To confirm NAT8L knockdown, transient 
transfection of several ovarian (HEYA8, SKOV3, A2780) and melanoma cell lines 
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(UACC 257, UACC 62, and M14) caused 60-96% knockdown of NAT8L gene 
expression at 48 hours (Figure 23).  
 
Figure 23. siRNA NAT8L knockdown  of NAT8L gene expression in ovarian 
and melanoma cancer cell lines.   Gene expression levels of NAT8L detected by 
RT-PCR.  RQ= relative real time quantitation.  Values are mean±SEM.  
 
We next evaluated the effect of NAT8L knockdown on cancer cell growth and 
survival.   We selected HEYA8 and A2780 cell lines in ovarian cancer as they had 
the highest knockdown of NAT8L using siRNA.  First, we evaluated the effect of 
NAT8L knockdown on cell viability (Trypan blue) after one [72 hours(3 days)] and 
two [144 hours(6 days)] rounds of transfections (Figure 24).  After the one round, 
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cell viability was decreased by 9.4% by siRNA NAT8L compared to the control non-
target siRNA (siRNA NT) (p<0.003).  After two rounds of transfections, cell viability 
was decreased by 24.0% by siRNA NAT8L compared to siRNA NT (p<0.01).  We 
also analyzed a synthetic lethality screen for chemotherapy resistant cell lines 
A2780-CP, HEYA8-MDR, and SKOV3-TR.  Surprisingly, after one round NAT8L 
knockdown and chemotherapy at 120 hours (Day 5), we saw a significant decrease 
in cell viability in all three chemo-resistant cell lines (Figure 25).  Thus, the effect of 
NAT8L knockdown in cancer cell viability using siRNA appears to occur after 5 days 
of treatment.  Therefore, we performed the remainder of our in vitro siRNA 
experiments with two rounds of transfections unless noted otherwise.  
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Figure 24.  Effect of siRNA NAT8L on cancer cell viability after one and two 
rounds of transfections.  Values are mean ±SEM. 
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Figure 25.  Cell viability with siRNA NAT8L compared to siRNA NT  in 
chemotherapy resistant cell lines.  Values are mean ±SEM. 
 
Trypan blue stains cells that are either dead or have damaged cell 
membranes; therefore we investigated if NAT8L knockdown increased cellular 
apoptosis.  Indeed, HEYA8 and A2780 showed that siRNA NAT8L had a significant 
increase of total apoptosis compared to siRNA NT by 38.53% (p<0.001) and 
37.85% (p<0.001), respectively (Figure 26).  To evaluate the in vitro generalizability 
of siRNA NAT8L, melanoma cell lines UACC 257, UACC 62, and M14 similarly 
showed an increase in apoptosis consistent with findings in ovarian cancer cell lines 
(Figure 27).  Furthermore, knockdown of NAT8L in combination with paclitaxel 
treatment displayed a synergistic effect on apoptosis (Figure 28).  Cells treated with 
paclitaxel and siRNA NAT8L had a 29.83% increase in apoptosis compared to 
paclitaxel and siRNA NT treated cells (p<0.001). 
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Figure 26.  Knockdown of NAT8L increases apoptosis in ovarian cancer cells.  
Values are mean ±SEM.  *= p<0.001. 
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Figure 27.  Knockdown of NAT8L increases apoptosis in melanoma cancer 
cells.  Values are mean ±SEM.  *= p<0.001. 
 
 
 
 
 
 
. 
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Figure 28. Knockdown of NAT8L increases sensitivity of paclitaxel’s effect on 
ovarian cancer cell apoptosis.  Values are mean ±SEM.  *= p<0.001 
 
On the basis that NAT8L is a putative GCN5 related gene (GCN5 is a 
ubiquitous histone acetyltransferase that promotes transcriptional activation), we 
investigated if NAT8L knockdown has an effect in cancer cell proliferation and cell 
cycle progression.   Indeed, ovarian cancer cells treated with siRNA NAT8L had a 
significantly decreased cell proliferation compared to siRNA NT (Figure 29a).  
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Proliferation decreased by 23.65% (p<0.001) and 19.13% (p<0.001) in A2780 and 
HEYA8 cells, respectively.  Furthermore, cells treated with siRNA NAT8L decreased 
cell cycle progression compared to siRNA NT.   HEYA8 cells with down-regulated 
NAT8L had an 8.4% increase in the number of cells with G1 phase (p<0.001), and 
an 11.65% decrease in the number cells in the S phase (p<0.001) (Figure 29b).  
Thus, knockdown of NAT8L decreased ovarian cancer cell’s ability to proliferate and 
progress through the cell cycle suggesting that NAT8L acetylation may have 
functions similar to histone acetyltransferases to promote transcriptional activation.    
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Figure 29.  Knockdown of NAT8L decreases cell proliferation and cell cycle 
progression.  Values are mean ±SEM.  *= p<0.001 
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On the basis that one of the proposed functions and association of NAA 
biosynthesis in the human brain is in cell energy production, we hypothesized that 
knockdown of NAT8L would decrease the levels of ATP in cancers cells.  We 
observed a significant decrease in ATP and ADP levels in HEYA8 cells treated with 
siRNA NAT8L, and a decrease of ADP in A2780 cells (Figure 30).  ATP levels 
decreased by 20.8% (p=0.03) in HEYA8 cells.  In A2780, although ATP levels were 
decreased by 13%, this was not statistically significant (p=0.17).  ADP levels were 
decreased by 19 %( p<0.001) and 32% (p=0.002) in HEYA8 and A2780 cells, 
respectively.  
 
Figure 30.  The effect of siRNA NAT8L on intracellular ATP and ADP.  Values 
are mean ±SEM. 
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Due to the decreased ATP and ADP levels in siRNA NAT8L, we hypothesized that 
this catabolic switch would significantly decrease cancer cell’s metastatic potential.  
Indeed, knockdown of NAT8L in HEYA8 cells significantly decreased migration and 
invasion by 91% and 92%, respectively (p<0.001) (Figure 31). 
 
.  
Figure 31.  Knockdown of NAT8L significantly decreased migration and 
invasion Values are mean ±SEM. 
 
To better understand the consequences of inhibiting NAA production on cancer 
cell gene and protein signaling, we evaluated siRNA NAT8L knockdown in HEYA8 
cells using a high throughput antibody based reverse phase protein array (RPPA) 
and high throughput gene expression array.  We used HEYA8 cell lines due to the 
fact that there was 96% knockdown of NAT8L from the siRNA, and its robust 
therapeutic response.  From our RPPA analysis, one of the largest effects of siRNA 
NAT8L was inhibition of negative cell death regulation, and increase in regulation of 
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kinase activity (Figure 32A).  One of the largest effects was down-regulation of AKT 
phosphorylation at Serine 479 and Threonine 308 suggesting that the anabolic and 
tumorigenic effects of this major oncogenic kinase were abrogated (Figure 32A).  
Furthermore in this network, significant inhibition in regulation of cell localization is 
predicted with decreases in paxillin, fibronectin, PKC-α, and Src phosphorylation at 
Y416 and Y527, thus suggesting decreased metastatic potential in cancer cells.  In 
the network of regulation of kinase activity, AMPK (PRKAA1) phosphorylation at 
Threonine 172 was dramatically higher with NAT8L knockdown.  Furthermore, there 
was high phosphorylation of acetyl-coA carboxylase (ACC) at residue position 
serine 79 which inhibits its activity (Figure 32A).  AKT is a major negative regulator 
of AMPK.  This indicates that knockdown of NAT8L switches HEYA8 cancer cells 
from an anabolic state to a catabolic state.  Since ACC is the major rate limiting 
enzyme reaction for de novo lipid synthesis, we evaluated the effect NAT8L 
knockdown on the cell’s fatty acid levels.  Cells were transfected with siRNA NAT8L 
lead to a dramatic decrease in cell fatty acids compared to NT siRNA (Figure 32B).  
NAT8L siRNA caused a 67.7% decrease of fatty acid levels compared to the NT 
siRNA (p=0.0004). 
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Figure 32.  Knockdown of NAT8L up-regulates switches cell to a catabolic 
state and decreases de novo lipogenesis.  Red boxes = upregulation, green 
boxes= down regulation, black boxes = no change.  Red circle = upregulation of 
protein levels, Yellow circle = upregulation of protein phosphorylation, Green ciricle= 
down regulation of protein levels, blue circle = down regulation of phosphorylation of 
protein.  *=p<0.001.   
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Hierarchical cluster analysis of integrated gene expression from siRNA 
NAT8L and siRNA NT had 1961 significantly different gene expression data 
(p<0.001) (Figure 33).  Network analysis showed significant decreases in a large 
number of genes involved in mitosis and the M phase of the cell cycle.    On the 
other hand, a number of genes involved in the catabolic processes were up-
regulated with NAT8L knockdown.  These gene and protein expression results 
indicate that one of the major roles of NAA biosynthesis involves regulation of cell 
division and growth in mitosis, and the absence of NAA biosynthesis confers a 
catabolic process in cancers cells decreasing its potential for proliferation, 
metastasis, and survival. 
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Figure 33.  Knockdown of NAT8L involves the negative regulation of cell 
division/mitosis and  positive regulation of  catabolic genes. Green boxes= 
down regulation of gene expression, Red boxes= up regulation of gene expression.  
Red circle = upregulation of gene expression levels, Green ciricle= down regulation 
of protein levels. 
 
 89 
 
Effect of NAA biosynthesis in orthotopic ovarian cancer mouse model 
On the basis of the clinical and in vitro findings, we evaluated the effect of siRNA 
NAT8L in orthotopic ovarian cancer models.  As compared to mice treated with 
siRNA NT, those treated with siRNA NAT8L had significantly decreased tumor 
growth (Figure 34a).  A2780 and HEYA8 orthotopic ovarian cancer model had an 
84.14% (p<0.001) and 69.17% (p<0.01) decrease in tumor weight, respectively.  
A2780 and HEYA8 mouse models also had statistically significant two-three fold 
reduction in the number of intraperitoneal tumor nodules.  We also observed a 
synergistic effect of siRNA NAT8L and paclitaxel (Figure 34b).   Using the HEYA8 
orthotopic in vivo model, siRNA NAT8L + paclitaxel had significantly less tumor 
burden  compared to siRNA NT(p<0.001), paclitaxel + siRNA NT (p=0.004), and 
siRNA NAT8L alone (p=0.032).  We also observed a decrease in the number of 
intraperitoneal tumor nodules with siRNA NAT8L + paclitaxel compared to siRNA 
NT (p=0.008), and siRNA NT + paclitaxel (p=0.020); however, no difference was 
observed between siRNA NAT8L alone and siRNA NAT8L + paclitaxel (p=0.611).  
To validate our in vitro data where siRNA NAT8L had significant effect on cell 
proliferation and apoptosis, we performed immunohistochemistry of ki67 and 
caspase-3 from our in vivo models.  Consistent with the in vitro findings, HEYA8 
tissues treated with siRNA NAT8L had significantly less proliferation (p<0.001) 
(Figure 35), and significantly more apoptosis (Figure 36).  IHC staining using 
cleaved-caspase 3 was increased by 2.46 fold in siRNA NAT8L compared to siRNA 
NT (p=0.003) (Figure 36a).  Although siRNA NAT8L + paclitaxel had a 1.57 fold 
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increase in apoptosis compared to paclitaxel treatment alone, this was not 
statistically significant (p=0.19) (Figure 36b). 
 
Figure 34.  Effect of siRNA NAT8L treatment in orthotopic ovarian cancer 
mouse models. Values are mean ±SEM.   
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Figure 35.  Effect of siRNA NAT8L on cell proliferation in HEYA8 orthotopic 
mouse model. Values are mean ±SEM.   
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Figure 36.  Effect of siRNA NAT8L +/- paclitaxel on apoptosis in HEYA8 
orthotopic mouse model.  Values are mean ±SEM. 
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To test the specificity and any possible off target effect of NAT8L siRNA, we 
did an experiment with two separate sequences of NAT8L siRNA in SKOV3 
orthotopic mouse model.  Our results showed that both NAT8L siRNA significantly 
reduced tumor burden.  Our first sequence and second sequences decreased tumor 
burden by 70% and 76%, respectively (Figure 37).  Furthermore, there were no 
significant differences in tumor burden between either NAT8L siRNA sequences.   
 
   
Figure 37.  SKOV3 orthotopic ovarian cancer mouse model.  Mice treated with 
DOPC NAT8L siRNA  using two different sequences. Values are mean ±SEM. 
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To evaluate the generalizability of NAT8L siRNA , we evaluated its effect in 
an A375-SM orthotopic melanoma mouse model.  Mice treated with NAT8L siRNA 
had a 62% decrease in tumor burden than the control mice.  This indicates that 
NAT8L siRNA decreases tumor growth in melanoma cancer by inhibiting NAA 
production.   
. 
 
Figure 38.  A375-SM orthotopic melanoma mouse model. Mice treated with 
DOPC NAT8L siRNA  and NT (control) siRNA.  Values are mean ±SEM.   
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Discussion 
Clinical Relevance of NAA production 
Our study is the largest metabolomics profile of high grade serous epithelial 
ovarian cancer (HGSOC) to date.  We observed an increase in glycolytic 
intermediates seen in the “Warburg effect”.  Furthermore, nearly 75% of the 
alterations involved lipid and amino acid pathways.  One of the most drastic up-
regulations involved is the neuron biosynthesized NAA metabolite which is derived 
from acetylation of aspartic acid which we detected in cultured ovarian cancer cells. 
More importantly, high levels of NAA and its biosynthetic enzyme NAT8L leads to 
worsening patient survival.  We observed that knockdown of NAT8L leads to 
significant decreases in tumor growth in an in vitro setting by decreasing tumor 
proliferation, cell cycle progression, increasing cellular apoptosis, and decreasing 
cancer cell invasion.   In the In vivo setting, siRNA NAT8L decreased tumor 
proliferation and increased apoptosis.  These findings along with the worsening 
clinical outcomes associated with high NAT8L gene expression in melanoma, 
breast, colon, lung squamous, renal clear cell, and uterine endometrial cancers 
provide compelling evidence that NAA production confers oncogenic properties, and 
functions as an oncometabolite. 
The overwhelming majority of metabolites altered in HGSOC involved lipid and 
amino acid metabolic pathways when compared to the normal ovary.  Eicosanoids 
and phospholipids were some of the highest fold changes in HGSOC highlighting 
the need for pro-inflammatory and pro-proliferative components.  PGE2 is the most 
up-regulated eicosanoid in HGSOC tissues.  PGE2 is the most abundant 
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prostaglandin in various cancers, and high levels are associated with worsening 
outcomes [183,184,185].  In colon cancer, PGE2 contributes to tumor growth by 
DNA methylation [186]. Interestingly, some essential diet derived fatty acids were 
elevated indicating, in addition to de novo lipogenesis, ovarian cancer cells also rely 
on the absorption of fatty acids from their microenvironment.  This is in accordance 
with a recent study showing that breast and prostate cancers absorb diet derived 
fatty acids to promote tumor growth and proliferation[187].  In ovarian cancer tumors 
metastasized to the omentum, up-regulation of Fatty Acid Binding Protein 4 
(FABP4) has been shown to significantly affect tumor growth and metastasis [123].  
Thus, emphasizing the importance of fatty acid uptake in ovarian cancer.  
Amino acid metabolism was the second most altered pathway in ovarian cancer 
with some of highest increases involving metabolites in the alanine/aspartate, 
glutamate/glutamine, and phenylalanine/tyrosine pathways suggesting that these 
are important amino acid pathways in HGSOC pathophysiology.  There is emerging 
evidence that many cancers have dysregulated amino acid metabolism that lead to 
tumor aggressiveness.  For example, cancer cells can divert glycolytic carbons into 
serine and glycine metabolic pathways [188].  The serine pathway has been found 
recently to be a major route for the conversion of glutamine to alpha-ketoglutarate 
for analeperosis in the TCA cycle to support tumor growth [66].  Glycine is used for 
de novo purine nucleotide synthesis in cancer cells [64].   
Our analysis of HGSOC amino acid pathways showed that NAA involved in the 
aspartate/alanine pathway to be the most up regulated metabolites.  The high up-
regulation of NAA in ovarian cancer compared to the normal ovary is consistent with 
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recent metabolomics studies [162,163,189].  In a study by Fong et al, NAA was 
elevated in primary ovarian cancer and even in greater amount in omental 
metastatic tumors compared to the normal ovary [162].  Interestingly, the primary 
ovarian cancer samples were from stage I-IIIC patients and omental metastatic 
tumors were from stage IIIC-IV patients suggesting that higher levels of NAA would 
be detected in more advanced cancers.  In a study by Ben Sellem et al, NMR 
analysis of serous, endometrioid, and mucinous cancers compared to the normal 
ovary showed specifically highest up-regulation of NAA in serous ovarian cancers. 
Furthermore, partial least square discriminant analysis  showed a clear separation 
of high grade (grade III) serous ovarian cancers from the normal ovary when 
compared to grade I and II [189].  In a study by Kolwijck et al, aspiration of ovarian 
cyst fluid (OCF) from serous, mucinous, endometrial, and clear cell  ovarian cancers 
showed that serous ovarian cancer had the largest concentrations of NAA.  
Furthermore, regardless of subtypes, patients with higher concentrations of NAA in 
OCF had more advanced stage disease (Stage III-IV).  Interestingly, NAA 
concentrations of OCF were also comparable to the malignant ascites levels[163].  
All of these studies suggest that high levels of NAA are associated with more 
advanced disease in ovarian cancer and the results of our study is the first direct 
evidence that high levels of NAA are in fact associated with worsening outcomes in 
HGSOC. 
However, some of our data differ from these previous studies [162,163,189].  
For example in our study of primary ovarian cancer samples (POC), NAA was up-
regulated 28 fold vs. 3 fold in the study by Fong et al [162] when compared to the 
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normal ovary.  Our POC were primarily from patients with advanced stage high 
grade epithelial ovarian cancers (Stages III-IV).  Fong et al’s POCs were mostly 
early stage ranging from Stage I-III.  However, when they compared omental 
metastatic ovarian tumors (Stage IIIC-IV) to the normal ovary, they detected a 
dramatically 85 fold increase in NAA suggesting more aggressive tumors have 
higher levels of NAA.  Second, the histopathologies of their ovarian 
adenocarcinomas were not specified, therefore making the metabolomics 
comparison to our HSOEC difficult.  Finally, our sample size of POC was larger with 
71 patients compared to 11 patients in their study.  In the study by Kolwijck et al, 
aspiration from OCF did detect NAA in serous borderline and benign tumors, and 
they did not detect a difference between NAA concentration in OTC between the 
malignant, borderline, or benign serous tumors[163].  There are several issues with 
interpretation and comparisons with our study.  First, this study was done in cystic 
fluid, and no tumor tissue was evaluated so it would be difficult to say where the 
source of NAA levels in serous borderline and benign tumors would be.  Second, 
there were only 9 serous ovarian cancer patients OTC evaluated, and no details 
about the grade of the tumor were available.  However, the authors did find 
significantly higher concentration of NAA in advanced stage disease compared to 
early stage disease.  This suggests that higher levels of NAA would be associated 
with worsening prognosis.   As we have shown in multiple large cohorts of ovarian 
cancer patients, at the gene-protein-metabolite level, high NAA production is 
significantly associated with worsening outcomes in HGSOC.  
 
 99 
 
Biologic relevance of NAA production 
This was the first time that the effects of NAT8L knockdown have been reported 
in cancer cells.  We observed that the knockdown of the NAT8L leads to significant 
decreases in tumor growth in the in vitro and in vivo setting by decreasing tumor 
proliferation, cell cycle progression, invasion/migration, and increasing cellular 
apoptosis.  Furthermore, knockdown of NAT8L resulted in up-regulation of the 
major metabolic regulator AMPK, and decreased activity of AKT and ACC in HEYA8 
ovarian cancer cells.  Metabolically, NAT8L knockdown decreased fatty acid levels 
in the cancer cell.  These results suggest that abrogation of NAA biosynthesis 
switches cancer cells from an anabolic to a catabolic state, thus decreasing 
cancer’s ability to proliferate and become more susceptible to cell death. 
It is noteworthy that similar results of tumor inhibition by activating the catabolic 
state in tumors by activating AMPK activity.  Drugs such as metformin have shown 
to activate AMPK activity, and cause cell cycle arrest and decreased cell 
proliferation in various cancers [124], metformin treated of several ovarian cancer 
cell lines caused cell cycle arrest and decreased cell proliferation.  Metformin 
caused a significant increase in AMPK phosphorylation and ACC phosphorylation 
enhancing fatty acid beta-oxidation and decreased lipid synthesis.  Interestingly, 
metformin’s anti-proliferative effects were seen both through an AMPK dependent 
and independent pathways.  In another study by Rattan et al [190], A2780 ovarian 
cancer orthotopic mice treated with metformin resulted in significant reduction of 
tumor growth with decreased tumor cell proliferation.  Furthermore, metformin 
significantly increased cisplatin cytotoxicity.  Moreover, the metformin treated group 
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had significantly increased activation of AMPK.  In a study of the ovarian cancer 
cells SKOV3 [191], the FASN inhibitor drug C93 caused significant increase in 
AMPK activation and a decrease in ACC activity.  As a result, fatty acid synthesis 
was decreased and glucose oxidation was increased possibly to conserve energy.  
This treatment worsened cell redox status causing cell death.  Furthermore, C93 
treatment of SKOV3 xenograft athymic mice showed significant anti-tumor effects 
and apoptosis.   
Although siRNA NAT8L treatment had similar effects on AMPK activity as 
metformin and C93, there were some differences that we have noted from our 
study.  The study by Rattan et al [124] showed anti-proliferative effects of metformin 
on various ovarian cancer cell lines (with the exception of SKOV3ip cell lines), 
unfortunately, no orthotopic model of these cell lines were included as validation in 
their study.  In a separate study by Rattan et al [190], an orthotopic in vivo model of 
A2780 with metformin did show anti-tumor effects.  However, there is a shortcoming 
for generalizability towards the more common high grade serous ovarian cancer; 
A2780 is an endometrioid ovarian cancer cell line.  In the study by Zhou et al [191], 
the in vivo model was a xenograft model rather than orthotopic model affecting its 
generalizability.  Furthermore, only one cell line was used for both in vitro and in 
vivo therapy.  In our study, the therapeutic implications of siRNA NAT8L were tested 
in several in vivo models.  We evaluated the effect of siRNA NAT8L in high grade 
serous and endometroid ovarian cancer cell lines. Furthermore, we evaluated the 
effect of siRNA NAT8L in several melanoma cell lines for generalizability.   
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Study limitations 
Although we show compelling evidence that abrogating NAA production will 
have anti-tumor effects by switching cancer cells from a catabolic to anabolic state, 
the mechanism of how NAA contributes to cell anabolism and survival remains 
unknown at this point.  Based on the protein and signaling alteration observed with 
knockdown of NAT8L, it would be helpful to profile HEYA8 cells to determine the 
metabolomics profile.  This would give further insight into the mechanism of how 
NAA production affects cancer cells from gene, protein, and metabolic levels.  
Another limitation related to the mechanism of NAA functioning in cancer cell is the 
question why NAA and NAT8L are elevated in cancer cells.  Our investigation is 
suggestive that NAA production is advantageous to cancer cells, and identifying the 
cause of NAA and NAT8L up-regulation elevation would be compelling to identify. 
Another limitation of our study is based on the assumption that high levels of 
NAA would be present in other cancers that are associated with worse outcomes 
with high NAT8L gene expression.  Although metabolomics profiling of human 
cancer tissues remains at its infancy, various metabolomics studies have shown 
significant up-regulation of NAA compared in invasive breast cancer and prostate 
cancer[65,192].   Furthermore, our clinical outcomes results of high NAT8L gene 
expression, and decreased tumor growth in our orthotopic melanoma mouse model 
treated with NAT8L siRNA, highly suggest that NAA levels would be high in several 
cancers promoting tumor growth.   
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Implications  
 From our study, we observed the increased expression of NAT8L in ovarian 
cancer compared to the normal ovary is a characteristic of this disease.  
Furthermore, from our clinical analysis, in vitro and in vivo experiments, we show 
that targeting NAT8L significantly inhibits tumor growth.  Therefore, ovarian cancer 
is associated with the genetic up-regulation of the NAA biosynthetic machinery to 
promote growth and survival of the tumor.   This unique characteristic of ovarian 
cancer not present in the normal ovarian tissue makes targeting NAT8L an 
attractive target to abrogating tumor growth and improving patient outcomes by 
blocking an important up-regulated cancer metabolic pathway.  A better 
understanding of molecular mechanisms of why some cancers are more dependent 
on NAA production would help in improving the efficacy of targeting this pathway.  
Furthermore, with the distinct elevation of NAA in ovarian cancer, there is 
promise that NAA may be used as a biomarker.   With advances of clinical MRS 
technology, our metabolic results have implications for the possibility of NAA as a 
potential novel biomarker in tumors outside of the CNS.  Recently, the novel 
oncometabolite 2-HG was shown to be detected in a non-invasive manner using 
MRS in glioma patients with IDH 1 and 2 mutations [193].  NAA would be an ideal 
marker in ovarian cancer due to its dramatic elevation compared to the normal 
ovary.  It would be interesting to see if MRS technology could aid in diagnosis of 
ovarian cancer in woman who present with ovarian masses.   Furthermore, the 
levels of NAA may be used in MRS techniques to assess response to 
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chemotherapy would be of use to assess. If NAA levels do decrease with therapy in 
ovarian cancer, then this holds great promise to use NAA as treatment biomarker.   
Finally, our study reveals that NAA is not only unique to brain metabolism, but 
also in the metabolism of cancer.  Since its discovery in 1956, NAA’s biological role 
has remained unclear and elusive.  The majority of studies related to NAA are in the 
area of NMR spectroscopy and its relationship to human brain pathologies.  
Diseases such as multiple sclerosis, cerebral vascular accidents, major head 
traumas, certain psychiatric conditions, and Canavan disease are all associated 
with deregulated NAA levels.  More studies looking into the biology and 
biochemistry is needed to help understand the mechanism of this abundant 
metabolite in the human brain and cancers.   
In conclusion, our study reveals that metabolic alteration in ovarian cancer 
involves mainly lipid and amino acid metabolic pathways.   Targeting unique 
pathways such as NAA production seems to have promising effects in abrogating 
the results of this metabolic alteration by inhibiting tumor growth and metastasis.  
Furthermore, our clinical and biologic studies of several cancer types revealed that 
NAA production seems relevant not only in ovarian cancer but also in several 
cancers, and further understanding of its mechanism would not only contribute to 
understanding of its role in cancer but also further an understanding of its role in the 
human brain.   
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